

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 1 154 443 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
14.11.2001 Bulletin 2001/46

(51) Int Cl.7: **H01F 1/00, H01F 1/44,  
C12N 15/10, C12Q 1/68,  
B03C 1/01**

(21) Application number: 00110165.8

(22) Date of filing: 12.05.2000

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(71) Applicant: **Roche Diagnostics GmbH**  
68305 Mannheim (DE)

(72) Inventor: **The designation of the inventor has not  
yet been filed**

(54) **Magnetic glass particles, method for their preparation and uses thereof**

(57) This invention relates to magnetic nanosized  
particles having a glass surface.

This invention also relates to methods for making

them, as well as to suspensions thereof and their uses  
for the purification of DNA or RNA in particular in auto-  
mated processes.

EP 1 154 443 A1

## Description

[0001] This invention relates to magnetic particles having a glass surface and are substantially spherical. This invention also relates to methods for making them, as well as to suspensions thereof and their uses for the purification of biological material in particular in automated processes.

[0002] Many biological materials, especially nucleic acids, present special challenges in terms of isolating them from their natural environment. On the one hand, they are often present in very small concentrations and, on the other hand, they are often found in the presence of many other solid and dissolved substances that make them difficult to isolate or to measure, in particular in biospecific assays.

[0003] Biospecific binding assays allow of the detection of specific analytes, e.g. nucleic acids, or specific analyte properties and play a major role in the field of diagnostics and bioanalytics. Examples therefor are hybridisation assays, immuno assays and receptorligand assays.

[0004] Hybridisation assays make use of the specific base-pairing for the molecular detection of nucleic acid analytes e.g. RNA and DNA. Hence, oligonucleotide probes with a length of 18 to 20 nucleotides may enable the specific recognition of a selected sequence in the human genome. Another assay which makes use of the selective binding of two oligonucleotide primers is the polymerase chain reaction (PCR) described in US 4,683,195. This method makes use of the selective amplification of a specific nucleic acid region to detectable levels by a thermostable polymerase in the presence of desoxynucleotide triphosphates in several cycles.

[0005] Nucleic acids are comparatively complex analytes which have normally to be extracted from complex mixtures before they can be used in a probe-based assay.

[0006] There are several methods for the extraction of nucleic acids:

- sequence-dependent or biospecific methods as e.g.:
  - affinity chromatography
  - hybridisation to immobilised probes on beads
- sequence-independent or physico-chemical methods as e.g.:
  - liquid-liquid extraction with e.g. phenol-chloroform
  - precipitation with e.g. pure ethanol
  - extraction with filter paper
  - extraction with micelle-forming agents as cetyl-trimethyl-ammonium-bromide
  - binding to immobilised, intercalating dyes, e.g. acridine derivatives
  - adsorption to silica gel or diatomic earths
  - adsorption to magnetic glass particles (MGP) or organo silane particles under chaotropic conditions

[0007] Many procedures and materials for isolating nucleic acids from their natural environment have been proposed in recent years by the use of their binding behavior to glass surfaces. In Proc. Natl. Acad. USA 76, 615-691 (1979), for instance, a procedure for binding nucleic acids in agarose gels in the presence of sodium iodide in ground flint glass is proposed.

[0008] The purification of plasmid DNA from bacteria on glass dust in the presence of sodium perchlorate is described in Anal. Biochem. 121, 382-387 (1982).

[0009] In DE-A 37 34 442, the isolation of single-stranded M13 phage DNA on glass fiber filters by precipitating phage particles using acetic acid and lysis of the phage particles with perchlorate is described. The nucleic acids bound to the glass fiber filters are washed and then eluted with a menthol-containing buffer in Tris/EDTA buffer.

[0010] A similar procedure for purifying DNA from lambda phages is described in Anal. Biochem. 175, 196-201 (1988).

[0011] The procedure known from the prior art entails the selective binding of nucleic acids to glass surfaces in chaotropic salt solutions and separating the nucleic acids from contaminants such as agarose, proteins or cell residue. To separate the glass particles from the contaminants according to the prior art, the particles are either centrifuged or fluids are drawn through glass fiber filters. This is a limiting step, however, that prevents the procedure from being used to process large quantities of samples.

[0012] It has been demonstrated that magnetic particles covered with a glass surface offer considerable advantages for isolating biological materials. If the magnetic particles have not been brought in contact with a magnetic field, gravity is the only force that can cause them to sediment out. They can be resuspended by shaking the solution. The sedimentation procedure that does not utilize a magnetic field proceeds more slowly than the immobilization of biological materials on the surface of the particles. This is especially true for nucleic acids. The magnetic particles can be easily collected at a specific location in the sample fluid by means of a magnet. The fluid is then separated from the particles

and, therefore, from the immobilized biological materials.

**[0013]** The use of magnetic particles to immobilize nucleic acids after precipitation by adding salt and ethanol is described in Anal. Biochem. 201, 166-169 (1992) and PCT GB 91/00212. In this procedure, the nucleic acids are agglutinated along with the magnetic particles. The agglutinate is separated from the original solvent by applying a magnetic field and performing a wash step. After one wash step, the nucleic acids are dissolved in a Tris buffer. This procedure has a disadvantage, however, in that the precipitation is not selective for nucleic acids. Rather, a variety of solid and dissolved substances are agglutinated as well. As a result, this procedure can not be used to remove significant quantities of any inhibitors of specific enzymatic reactions that may be present. Magnetic, porous glass is also available on the market that contains magnetic particles in a porous, particular glass matrix and is covered with a layer containing streptavidin. This product can be used to isolate biological materials, e.g., proteins or nucleic acids, if they are modified in a complex preparation step so that they bind covalently to biotin. Magnetizable particular adsorbents proved to be very efficient and suitable for automatic sample preparation. Ferrimagnetic and ferromagnetic as well as superparamagnetic pigments may be used for this purpose.

**[0014]** Particles, according to the expert, are solid materials having a small diameter. Particles like these are often also referred to as pigments.

**[0015]** Those materials are referred to as magnetic that are drawn to a magnet, i.e., ferromagnetic or superparamagnetic materials, for instance. Superparamagnetism is seen as advantageous and preferable in the state of the art (e.g. US 5,928,958; US 5,925,573; EP 757 106). The glass or organosilane surfaces are often functionalised in order to be used for biospecific capture reactions, e.g. US 5,928,958, US 5,898,071, US 5,925,573, EP 937 497, US 4,554,088 or US 4,910,148. Alternatively, glass or organosilane surfaces may be treated with various solvents or salts to modify their hydrophilicity and/ or electropositivity, e.g. US 5,438,127.

**[0016]** However, the underivatized silanol groups of the glass or the silane surface may be used for the adsorption with pure physico-chemical forces under suitable reaction conditions as described in DE 195 20 964, DE 195 37 985, WO 96/41840, WO 96/41811, EP 757 106 or US 5,520,899. Typically, magnetic cores or magnetic core aggregates are covered with a glass surface which is formed by an acid- or base-catalyzed sol-gel-process. These particles are called core-shell particles. The glass shell then has a typical layer thickness (see e.g. DE 195 20 964) wherein the size and shape of the pigment, which may contain a non-magnetic support as e.g. mica in addition to the magnetic metal oxide, determines size and form of the produced particle (see e.g. DE 195 37 985 and corresponding WO 96/41811). To obtain a high surface activity, glass material with a high porosity is used (see e.g. EP 757 106; WO 99/26605). Further, composite magnetic particles are described, e.g. silicate-covered ferric oxide covered with an inorganic silica matrix from silica particles (EP 757 106) or mixtures of glass and silica gel (WO95/ 06652).

**[0017]** The problem to be solved by the present invention can be seen as providing magnetic glass particles with improved properties for sample preparation and for biological assays, in particular for automated processes.

**[0018]** The deficiencies of the magnetic glass particles in the state of the art are overcome by the findings of the present invention.

**[0019]** It is an object of the invention to provide a composition of magnetic glass particles. The magnetic glass particles (MGPs) according to the present invention are a solid dispersion of small magnetic cores in glass. The MGPs are comparatively small and are substantially spherical. The non-magnetic fine content of a composition of the MGPs is very low because of the method of their preparation. This has the effect that suspensions of the MGPs sediment slowly and can therefore be advantageously used for processes in molecular biology which can be automatized. In one embodiment of the invention compositions and suspensions of the MGPs according to the present invention are provided. In another embodiment of the invention a method for the composition of the MGPs is provided. In still another embodiment of the invention a method for the purification of DNA or RNA is provided in which the MGPs according to the present invention are used.

**[0020]** It is a object of the present invention to provide a composition of magnetic glass particles which are substantially spherical and have a small diameter and contain at least one magnetic object with a diameter between 5 and 500 nm. This has surprising consequences on the sedimentation kinetics, quantified by the half time values  $t_{1/2}$ , which is the time span until 50 % of the particles have sedimented from a specific volume element (see Example 6). The half-life period for the sedimentation of a 3 mg/ml weight-per-volume suspension of the composition in isopropanol is more than 3 min, preferably 4 min, more preferably 6 min. However the most preferred values for the half-life period is more than 10 min or even more than 20 min. The smaller and closer to the ideal sphere, the longer the MGPs will be suspended. This may be explained by the fact that the closer the form will resemble an ideal sphere, the lower the possibility that two or more particles will stick together and built up aggregates which may sediment more rapidly. These data are shown in Example 6 and high resolution scanning electron microscopical images can be seen in Figure 4 to Figure 10. This has the advantage that for automated processes the required mixing intensity and mixing frequency of the storage containers containing the MGP suspension is reduced as the repetitive dosage of a specific MGP suspension volume from a surplus volume sucked into a syringe is easier (more precise delivery with regard to  $\text{mass}_{\text{MGP}} / \text{volume}$ ).

**[0021]** The MGPs according to the present invention are glass droplets in which very small non-aggregating magnetic

objects are dispersed. Those objects that are referred to as magnetic are drawn to a magnet, i.e., ferromagnetic or superparamagnetic materials, for instance. Preferred are ferromagnetic materials, in particular if they have not yet been premagnetized. Premagnetization in this context is understood to mean bringing in contact with a magnet, which increases the remanence. Preferred magnetic materials are iron or iron oxide as e.g. magnetite ( $\text{Fe}_3\text{O}_4$ ) or  $\text{Fe}_2\text{O}_3$ , preferably  $\gamma\text{-Fe}_2\text{O}_3$ . In principle, barium ferrite, nickel, cobalt, Al-Ni-Fe-Co alloys or other ferri- or ferromagnetic could be used. The magnetic objects may be e.g. a magnetic pigment. The size of the magnetic objects is in the nanoscale range, i.e. according to the present invention the diameter is between 5 to 500 nm, preferably between 10 to 200 nm, most preferably between 15 to 50 nm. Suitable magnetic pigments are manufactured by the company CERAC which have a mean diameter of 23 nm and consist of  $\gamma\text{-Fe}_2\text{O}_3$  (BET-surface  $50 \text{ m}^2/\text{g}$ , CERAC: P.O. Box 1178, Milwaukee, Wisconsin 53201-1178 USA; Article-No. I-2012). The magnetic glass particles according to the present invention are further characterized by the fact that the MGPs have a particle diameter between  $0.5 \mu\text{m}$  and  $5 \mu\text{m}$ , preferably between  $1 \mu\text{m}$  to  $2 \mu\text{m}$  as determined by high resolution scanning electron microscopy, whereas the magnetic objects have a diameter between 5 to 500 nm, preferably between 10 to 200 nm, most preferably in the range of 15 to 50 nm as said above. Hence, the MGPs of the present invention are further characterized by a diameter ratio of magnetic pigment core to magnetic glass particle of less than 1 to 10 as determined by high resolution scanning electron microscopy. Because of these diameter ratios as well as the absence of any inert carrier that would determine shape and size of the particles, the geometry of the MGPs and the number of incorporated magnetic objects, are determined by the conditions of manufacturing. The MGPs according to the present invention are microporous but have highly-structured and therefore relatively large surface with more than  $6 \text{ m}^2/\text{g}$ . Preferably, the magnetic glass particles according to the present invention have a surface area in the range of 5 to  $100 \text{ m}^2/\text{g}$ , preferably 5 to  $90 \text{ m}^2/\text{g}$ , more preferably in the range of 10 to  $50 \text{ m}^2/\text{g}$ , most preferably in the range of 15 to  $30 \text{ m}^2/\text{g}$ . This surface is approximately double the size of the particles described in DE 195 37 985. This can be determined by the Braunauer-Emmett-Teller-method using an automated commercial apparatus (see Example 4). For a discussion of this method, familiarly called the BET method, see S. Braunauer. The Adsorption of Gases and Vapors, Vol. 1, Princeton University Press, 1943. For example, the sample EJ0096.5R-01 which is of preferential interest (see Example 1 and Table 1 to Table 3 for a summary of the production parameters) has a BET-surface of  $26.8525 \text{ m}^2/\text{g}$ , a micropore area of  $2.3058 \text{ m}^2/\text{g}$  and an average pore diameter of  $24.9132 \text{ nm}$ . This means that the pore surface is less than 10 % of the total surface and that the magnetic glass particle is microporous.

**[0022]** A pore is understood to be a recess in the outer surface of the particle. The surface reaches so far into the particle that a perpendicular line drawn in the recess on the surface cuts the particle at least once in the direction of the adjacent environment of the particle. In addition, pores reach into the particle to a depth that is greater than one radius of the pore.

**[0023]** The slower sedimentation kinetics, larger surface and the aggregation-inhibiting spherical form manifest themselves in the better functional performance as adsorbent in the nucleic acid diagnosis (see Example 3, 5 and 7) when compared to the German patent applications DE 198 54 973.3 or DE 198 55 259.9. This criterion can be quantified by a shift of the threshold cycles in so-called TaqMan® assays, the signal-to-noise ratio and of the statistically validated lower detection limit. The methods for this assay are disclosed in WO92/02638 and the corresponding US patents US 5,210,015, US 5,804,375, US 5,487,972). Radiotracing experiments (see Example 5.2) showed that the binding behavior with regard to DNA and RNA was the same when compared to reference material known in the state of the art. Surprisingly, the production parameters had an influence on the performance in the radiotracing experiments. A further advantage of the MGP-type of the present invention is that no tensions in the glass layer can lead to fissure during the drying process and corresponding damages in the glass shell because of the inner structure (solid dispersion of small magnetic cores in a glass drop). This can be investigated by image-producing methods (see Example 3).

**[0024]** Another embodiment of the present invention is a suspension of magnetic particles. It is obvious for the person skilled in the art to produce a suspension by adding a liquid to a composition of the MGPs and mix the suspension to homogeneity. A liquid according to the present invention may comprise any liquid which does not affect the stability of the magnetic particles and may be used to produce a homogenous suspension.

**[0025]** Preferably liquids are used which are suitable for processes in molecular biology, in particular desoxyribonucleic acid (DNA) or ribonucleic acid (RNA) purification processes which make use of the binding of these substances to glass particles under certain conditions. Preferred liquids comprise alcohols or any mixtures thereof with water or ketones. Alcohols shall include according to the invention preferably primary, secondary or tertiary alcohols of the general formula  $\text{R-OH}$  where the R stands for the general formula  $\text{-(CH}_2\text{)}_n\text{-CH}_3$  with  $n \geq 0$ . However, other alcohols can also be used if they are suitable for molecular biology purposes as e.g. glycerol. Particularly suitable are the alcohols isopropanol, ethanol or mixtures thereof with water, preferably a mixture of 80 volume parts of isopropanol with 20 volume parts of water. In another embodiment of the invention the liquid comprises ketones as e.g. acetone. In a preferred embodiment of the invention these suspensions contain between 5 to  $60 \text{ mg/ml}$  MGPs. In another embodiment of the invention the MGPs are suspended in aqueous buffered solutions which may optionally contain a chaotropic agent in a concentration of between 2 and  $8 \text{ mol/l}$ , and preferably between 4 and  $6 \text{ mol/l}$ . Chaotropic salts

can be sodium iodide, sodium perchlorate, guanidinium thiocyanate, guanidinium isothiocyanate or guanidinium hydrochlorite. Other compounds are also possible. A chaotropic agent according to the present invention will be any chemical substance which will disturb the ordered structure of liquid water and will have the effect that DNA or RNA will bind to the MGPs according to the present invention if this agent is present in the DNA or RNA containing solution. It is obvious for the artisan to produce suitable aqueous buffered solutions. Buffer systems which may be used for molecular biology purposes may be found e.g. in Sambrook et al. (1989), Molecular Cloning, Cold Spring Harbor University Press, New York, NY, USA. Preferred buffer substances are Tris-hydroxymethylamine (TRIS), phosphate, N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES), salts thereof or other suitable substances. Additionally, substances may be present which modify the ionic strength of the solution as e.g. NaCl, KCl or CaCl<sub>2</sub> or which are metal cation complexing agents as e.g. ethylene-diamine-tetra-acetic acid (EDTA) or the salts thereof. Biological material known to the expert in the field may also be present. In another embodiment of the invention the suspension of MGPs may additionally contain DNA or RNA optionally in a mixture with proteins, fatty acids, carbohydrates and other material from biological origin. In another embodiment of the invention the liquid may contain a mixture of one or more constituents selected from the group of alcohols, ketones, aqueous buffered solutions, chaotropic agents, substances which modify the ionic strength of the solution, complexing agents, biological material, DNA or RNA all with the features as described above.

**[0026]** In another embodiment of the invention a tube or reaction vessel containing the suspension according to the invention is provided. The tube can be made of plastics but it may also be part of a larger structure, e.g. part of a microtitreplate in 96- or 384-wellformat. In still another embodiment of the invention a storage container is provided which contains a composition of magnetic glass particles or suspensions thereof.

**[0027]** In another embodiment of the invention a kit of parts is provided which comprises a storage container containing the magnetic glass particles or a suspension thereof according to the present invention. The kit may be used for the purification of DNA or RNA. Such kits known in the art further comprise plastics ware which may be used during the purification procedure as e.g. microtitreplates in the 96 or 384 well format or just ordinary reaction tubes manufactured e.g. by Eppendorf, Hamburg, Germany. The kit may further comprise a washing solution which is suitable for the washing step of the magnetic glass particles when DNA or RNA is bound thereto. Often the washing solution is provided as a stock solution which has to be diluted before the use. The kit may further comprise an eluent, i.e. a solution or a buffer (e.g. TE, 10 mM Tris, 1 mM EDTA, pH 8.0) or pure water to elute the DNA or RNA bound to the magnetic glass particles. Further, additional reagents may be present which can be used for the purification process of a nucleic acid, i.e. DNA or RNA. In one embodiment of the invention the kit of parts according to the present invention is used for the purification of a nucleic acid.


**[0028]** In one embodiment of the invention the composition of MGPs may be used to produce a suspension as already described.

**[0029]** In another embodiment of the invention the suspensions according to the present invention may be used for the purification of nucleic acids, i.e. RNA or DNA, from complex mixtures with other biological substances containing them. Thereby also mixtures of different nucleic acids may be purified, even mixtures containing a nucleic acid of interest in low abundance. The purification effect results from the behavior of DNA or RNA to bind to magnetic glass particles under certain conditions e.g. in the presence of certain concentration of a chaotropic agent. Preferably, the MGPs with the bound DNA or RNA are washed afterwards at least once, preferably with a mixture of 70 volume parts ethanol with 30 volume parts water ("70 % Ethanol"). Afterwards, the conditions are reversed, e.g. the concentration of the chaotropic agent is decreased, to elute the DNA or RNA bound to the MGP the particle. Preferably, this is done by the pelleting of the magnetic glass particles, e.g. by gravity force or by the use of a magnet, and resuspending in a solution with no or only a low amount of chaotropic agent.

**[0030]** Alternatively, the solution can be diluted with a solution with no or only a low amount of chaotropic agent. The purified DNA or RNA can now be used for other reactions.

**[0031]** It is one object of the invention to provide a production method for the MGPs according to the present invention. A glass according to the present invention is understood to be an amorphous material that contains silicium. Glass can contain other materials such as B<sub>2</sub>O<sub>3</sub> (0 - 30%), Al<sub>2</sub>O<sub>3</sub> (0 - 20%), CaO (0 - 20%), BaO (0 - 10%), K<sub>2</sub>O (0 - 20%), Na<sub>2</sub>O (0 - 20%), MgO (0 - 18%), Pb<sub>2</sub>O<sub>3</sub> (0 - 15%). Glass can also contain a smaller percentage (0 - 5%) of a number of other oxides such as Mn<sub>2</sub>O<sub>3</sub>, TiO<sub>2</sub>, As<sub>2</sub>O<sub>3</sub>, Fe<sub>2</sub>O<sub>3</sub>, CuO, CoO, etc.






**[0032]** Especially preferred according to the present invention are glasses that are formed using the gel sol process described in WO 96/41811 and then dried and compressed. The basic principles of this process are known and were described, for instance, in C.J. Brinker, G.W. Scherer "Sol Gel Science - The Physics and Chemistry of Sol Gel Processing", Academic Press Inc. 1990, Sol-Gel Optics, Processing and Applications, Lisa C. Klein, Ed., Kluwer Academic Publishers 1994, p. 450 ff., and in DE-A-1941191, DE-A-3719339, DE-A-4117041, DE-A-4217432 and WO96/41811. Principally, in the gel-sol process, alkoxides of network-forming components, e.g., SiO<sub>2</sub>, B<sub>2</sub>O<sub>3</sub>, Al<sub>2</sub>O<sub>3</sub>, TiO<sub>2</sub>, ZrO<sub>2</sub>, GeO<sub>2</sub>, are combined with oxides and salts of other components, e.g., in an alcohol solution, and then hydrolyzed. The equation below describes the procedure for making sodium boroaluminium silicate glass:







Water is added to begin the hydrolysis process of the starting components. The reaction proceeds relatively quickly because the alkali ions have a catalytic effect on the speed of hydrolysis of the silicic acid ester. Once the gel is formed it can be dried and densified (or condensed) by means of a thermal process to form glass.

[0033] In one embodiment of the invention the glass matrix will be produced by acid or base catalyzed sol-gel synthesis as shown schematically in Figure 1 and Figure 2 and described in detail in Example 1. Here, use is made of colloidal systems wherein at first the solid constituents are dispersed in the liquid phase (=sol) and after the processing they are interconnected like a honeycomb pattern (=gel). The composition of the glass (code EJ) as calculated from the quantity of the educts was 70,67 Mol% SiO<sub>2</sub>, 14,33 Mol% B<sub>2</sub>O<sub>3</sub>, 5,00 Mol% Al<sub>2</sub>O<sub>3</sub>, 4,00 Mol% K<sub>2</sub>O, 2,00 Mol% CaO, 4,00 Mol% ZnO. The composition of the glass (code RN) was 74 Mol% SiO<sub>2</sub>, 15 Mol% B<sub>2</sub>O<sub>3</sub>, 5,00 Mol% Al<sub>2</sub>O<sub>3</sub>, 4,00 Mol% K<sub>2</sub>O, 2,00 Mol% CaO. The composition of the glass (code EP) was 73,61 Mol% SiO<sub>2</sub>, 14,93 Mol% B<sub>2</sub>O<sub>3</sub>, 5,21 Mol% Al<sub>2</sub>O<sub>3</sub>, 4,17 Mol% K<sub>2</sub>O, 2,08 Mol% CaO.


[0034] The reaction may be described as follows:  
either acid-catalyzed, e.g.:



or alkaline-catalyzed, e.g.





[0035] The diverse hydroxides condensate to the corresponding oxides which form a three-dimensional network, the amorphous glass matrix of  $\text{SiO}_2$  /  $\text{B}_2\text{O}_3$  /  $\text{Al}_2\text{O}_3$  with metal ions occupying interstitial sites. In addition to the above-captioned alkaline and alkaline earth metal ions, transition metal ions as e.g.  $\text{Zn}^{2+}$  and  $\text{Zr}^{2+}$  may be incorporated in the matrix as network modifying agents.



[0036] In another embodiment of the invention, the glass may be produced with methods known in the state of the art by the melting of the raw material  $\text{SiO}_2$  and of carbonates of the alkali or alkaline earth metals  $\text{Na}_2\text{CO}_3$ ,  $\text{K}_2\text{CO}_3$  or  $\text{CaCO}_3$ .

[0037] The reaction may be described as follows:



[0038] However in most cases, there is no pure silicate matrix but a borate-aluminate-silicatematrix i.e. regarding the network building constituent a part of  $\text{SiO}_2$  is substituted by  $\text{B}_2\text{O}_3$  and  $\text{Al}_2\text{O}_3$ .

[0039] The sol: pigment ratio has a considerable effect on the yield of magnetic particles provided by this invention. It is essential for the process that the sol can still be pumped and sprayed which is in the skill of artisan.

[0040] To create a powder, the slurry is preferably sprayed through a two-fluid nozzle as described in Figure 1 and in Example 1.3. Suitable spray-drying systems are produced by Nubilos Molekularzerstäubung, Ladisch GmbH & Co. KG, Konstanz, Germany, e.g. the "Labor-Zerstäubungstrockner (Typ LTK)" or by Büchi AG, Uster, Switzerland, e.g. the Mini Spray Dryer (Type B-191).

[0041] Because of the diameter ratios of magnetic cores to the glass shell are less than 1 to 10, preferably between 1:10 and 1:1000, the geometry and the number of incorporated magnetic cores or of their inert carriers do not determine shape and size of the particles but the conditions of manufacturing, in particular the conditions during spray drying.

[0042] In other words, the choice of pressure, inlet temperature, outlet temperature and flow rate during the spray drying procedure are the degrees of freedom which will determine the size distribution, the shape of the glass drops and thereby will modify the MGPs.

[0043] When the spray pressure is increased, the size distribution will shift into the sub-µrange. The decreased temperature of the spray drying process will lead to slower evaporation of the solvent and thereby the form of the MGPs will come closer to an ideal sphere, i.e. the ratio of the radii in xy- and xz-plane will become approximately 1. The ratio of the radii will vary between 0,8 and 1,2, preferably between 0,9 and 1,1.

[0044] In a preferred embodiment of the invention the nozzles are heated. The inlet temperature is between 120 °C and 500 °C, preferably between 170 °C and 230 °C or 150 °C and 230 °C, most preferably between 150 °C and 200 °C or 190 °C and 210 °C or at 200 °C or slightly less. The outlet temperature depends on the boiling point of the sol and thereby on the solvent and may be above, equal or slightly under, i.e. less than 10°C, the boiling point of the solvent. When ethanol is used as solvent, it is between 50 °C and 300 °C, preferably 70 °C and 150 °C, most preferably



between 80 °C and 110 °C. The optimal temperature is between 90 °C to 100 °C. The nozzle pressure is more than 3 bar, preferably it is regulated to 4 to 6 bar. The artisan will appreciate the fact that the exact parameters will depend on the spray-drying system used. However, he can transfer the teachings of the present invention to any other spray-drying and find out the parameters by taking the disclosures of this invention into account. Formula as described in Masters: Spray Drying Handbook, Fifth Edition, John Wiley & Sons, 1991, New York can lead him the way to find out which parameters have to be chosen for another setting. Preferably, he will question the manuals of his spray-drying system or contact the technical service of the spray-drying system manufacturer.

**[0045]** To optimize the yield, the densification or sinter temperature should be as high as possible, i.e. slightly below the melting range. If it is too high, however, the particles will stick together and form agglomerates that must be sieved out. If too low, the MGPs will not be optimally densified. Additional treatment of the particles at too high temperature will result in a loss of magnetic properties. Too high temperatures should therefore be omitted. The exact temperatures depend on the glass composition but may be between 400°C to 1200°C. In the case of the EJ glass composition the sinter temperature is between 720°C and 770°C, preferably around 750°C. It is in the skill of the artisan to find out the temperatures for each glass composition when taking the teachings of the present invention into account. According to the present invention, the spray-dried MGP powder may be further processed as depicted in Figure 2 and described in Example 1.4. Preferably, the powder is heated for 1 hour to 200 °C, optionally cooled to room temperature and heated to 750 °C (densification or sinter temperature) in a nitrogen atmosphere with a heating rate of 1 K/min and is held at that temperature for 1 hour. Then the furnace is cooled to 150 °C and heated again to 200 °C for one hour in air. After the cooling to room temperature, the powder is transferred to a sieve (50 µm) and sieved for 30 min. The sieved sample is bottled and sterilized at 200 °C for 4 h and then cooled to 80 °C. Then the glass vessels are taken from the oven, covered with sterile foil and closed.

**[0046]** Surprisingly, the magnetic particles provided by the invention are especially suited for isolating biological materials from samples. In addition, the core material is a natural resource and therefore causes little ecological concern. Moreover, the particles according to the invention are inexpensive and easy to manufacture.

**[0047]** Another object of the invention is a procedure for isolating a biological material by bringing a sample containing the biological material in a liquid in contact with the magnetic particles according to the invention under conditions in which the biological material binds to the particle surface, and separating the biological material from the liquid. According to the invention the term "in a liquid" means that liquid may be added to the sample before the magnetic particles are added. However, it shall also comprise the situation when the sample itself has a low viscosity and is itself a liquid so that no additional liquid or buffer may have to be added to the sample for the sample preparation which may be done by adding solid agents before the magnetic glass particles are added. The order of reagent addition may be varied according to process requirements.

**[0048]** Biological materials are understood to mean materials with a particular or molecular basis. They include, in particular, cells such as viruses or bacteria, as well as isolated cells from multicellular organisms as e.g. human and animal cells such as leucocytes, and immunologically active low and high molecular chemical compounds such as haptens, antigens, antibodies and nucleic acids. Nucleic acids such as DNA or RNA are especially preferred. In one embodiment of the invention mixtures of specific nucleic acids are purified, in which the target nucleic acid(s) may be a minor component in terms of concentration (or may be present in low abundance). According to the present invention, a target nucleic acid shall be the nucleic acid of interest, i.e. a nucleic acid which shall be investigated as its presence is indicative of a certain condition or disease of a human or animal. For example, the presence of a viral sequence (e.g. from Hepatitis B Virus, Hepatitis C Virus or Human immunodeficiency virus) indicates that the respective individual is infected by the specific virus. Then, this viral sequence would be the target sequence. Other target sequences are sequences which are indicative of a predisposition of an individual to a certain disease as e.g. an inherited disease as sickle cell anemia or to certain types of cancer. This examples should be illustrative of the invention but should not be delimiting.

**[0049]** Samples according to the invention include clinical samples such as blood, serum, oral rinses, urine, cerebral fluid, sputum, stool, biopsy specimens and bone marrow samples. The sample can also be of a type used for environmental analysis, food analysis or molecular biology research, e.g., from bacterial cultures, phage lysates and products of amplification procedures such as the PCR.

**[0050]** The procedure described can be used to isolate native or modified biological material. Native biological material is understood to be material, the structure of which was not irreversibly changed compared with the naturally-occurring biological materials. This does not mean that other components of the sample can not be modified, however. Modified biological materials include materials that do not occur in nature, e.g., nucleic acids that are modified by attaching to them groups that are reactive, detectable or capable of immobilization. An example of this are biotinylated nucleic acids.

**[0051]** In certain cases the sample can be used without pretreatment in the isolation procedure according to the invention. In many cases, however, the sample should be lysed using an appropriate method, releasing the biological material contained in the sample. Procedures for lysing samples are known by the expert and can be chemical, enzy-

matic or physical in nature. A combination of these procedures is applicable as well. For instance, lysis can be performed using ultrasound, high pressure, by shear forces, using alkali, detergents or chaotropic saline solutions, or by means of proteinases or lipases. With regard for the lysis procedure to obtain nucleic acids, special reference is made to Sambrook et al.: Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY and Ausubel et al.: Current Protocols in Molecular Biology 1987, J. Wiley and Sons, NY.

**[0052]** In addition to the biological material to be isolated, the sample can also contain other components in a liquid such as cell residue, proteins, salts and other substances that are not to be isolated. This sample, which preferably contains the biological material in native form, is brought in contact with the particles under conditions in which the target biological material binds to the particle surface. The conditions for this depend on the type of biological material involved, but are basically known. They also depend on the method by which the biological material is bound to the surface. If immunological interactions are utilized for the binding, for instance, conditions must be selected that are suitable for the formation of immunocomplexes. If modified nucleic acids are used, the binding can take place via the groups of nucleic acids that represent the modification, e.g., biotin via binding with streptavidin-coated surfaces. With nucleic acids in particular, however, a direct binding of nucleic acids to glass is preferred because among other reasons the nucleic acids do not have to be modified and even native nucleic acids can be bound. The procedure for binding native nucleic acids to glass particles can be analogous to the procedure described in the prior art. It is preferably performed in the presence of chaotropic salts with a concentration of between 2 and 8 mol/l, and preferably between 4 and 6 mol/l. Chaotropic salts can be sodium iodide, sodium perchlorate, guanidinium thiocyanate, guanidinium isothiocyanate or guanidinium hydrochlorite. Other compounds are also possible.

**[0053]** To bring the sample in contact with the particles, the sample is mixed with the particles and incubated for a period of time sufficient for the binding to occur. Experts are usually familiar with the duration of the incubation step from procedures for performing treatment with non-magnetic particles. This step can be optimized by determining the quantity of immobilized biological material on the surface at different points in time. Incubation times of between 10 seconds and 30 minutes can be appropriate for nucleic acids.

**[0054]** Depending on the size and type of magnetic particles, the particles either separate out of the fluid during the incubation period itself or the suspension remains intact for a longer period of time. If the particles are very small and unmagnetized, the suspension remains intact for a longer period of time. If the particles are of larger size, the particles slowly separate out of the fluid during the incubation period.

**[0055]** Immobilization is preferably not performed via precipitation by lowering the solubility of the materials to be immobilized. Rather, immobilization is based on biospecific interactions (capture molecules) or adsorption. This largely prevents contaminants from being non-specifically included.

**[0056]** After incubation, the biological material is separated from the liquid. This is achieved in general by separating the material bound to the magnetic particles by applying a magnetic field. For instance, the magnetic particles can be pulled to the wall of the vessel in which incubation was performed. The liquid containing the sample contents that were not bound to the magnetic particles can then be removed. The removal procedure used depends on the type of vessel in which incubation was performed. Suitable steps include removing the liquid via pipetting or aspiration.

**[0057]** The magnetic particles can then be purified one or more times using a wash solution, if desired. A wash solution is used that does not cause the biological material to be released from the particle surface but that washes away the undesired contaminants as thoroughly as possible. This wash step preferably takes place by incubating the wash solution with the particles. The particles are preferably resuspended during this step, e.g., by means of shaking or applying a magnetic field that is not identical to the first magnetic field. The contaminated wash solution is preferably separated just like the sample in the step described above for binding the biological material.

**[0058]** After the last wash step, the magnetic particles can be dried briefly in a vacuum, or the fluid can be allowed to evaporate. A pretreatment step using acetone may also be performed. If desired, the biological material purified in this manner can be separated from the magnetic particles. This step also depends on the manner in which the biological material was bound to the magnetic particles. If the biological material is native nucleic acids and the magnetic particles are glass-coated particles, the nucleic acids can be removed from the particles according to the invention using an elution buffer having a low salt content. Buffers of this nature are known from DE 3724442 and Analytical Biochemistry 175, 196-201 (1988). The elution buffers with a low salt content are in particular buffers with a content of less than 0.2 mol/l. In an especially preferred embodiment, the elution buffer contains Tris. In another special embodiment, the elution buffer is demineralized water.

**[0059]** In yet another embodiment, the purification and isolation procedure described is performed after the cells (e.g., viral particles or prokaryotic or eukaryotic cells) are separated immunomagnetically from a bodily fluid or tissue. In this step, the sample is incubated, e.g., while shaking, with magnetic particles to which an antibody against an antigen on the cell is immobilized. These particles can be particles according to the invention or commercially available particles (e.g., MACS Microbeads from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). After a magnetic field is applied, one or more wash steps are performed using a saline solution. Particles are obtained to which the desired cells are bound. The bound cells are then resuspended in a saline buffer. In a preferred embodiment, this saline buffer is a

chaotropic saline solution so that the nucleic acids contained in the cell are released from the cells.

**[0060]** An especially advantageous procedure for isolating nucleic acids from samples containing cells is achieved by combining the isolation of cells described above with the isolation of nucleic acids also described above, on the magnetic particles according to the invention. The advantage of this embodiment is its potential simplicity (single-tube method), high sensitivity (especially important in medical microbiology and oncology), and the ease with which it can be automated.

**[0061]** The biological materials isolated using the procedure according to the invention can now be used further as necessary. For instance, they can be used as a substrate for various enzymatic reactions. When nucleic acids are involved, they can be used for sequencing, radioactive or non-radioactive labelling, amplification of one or more of the sequences they contain, transcription, hybridization with labelled probe nucleic acids, translation or ligation. An advantage of the procedure according to the invention is that it is very easy to separate the biological material from the fluid. In the prior art, a centrifugation step was used to separate the glass particles from contaminants, or, when the biological material is bound to glass fiber filters, the fluid is drawn through the filters. This is a limiting step that makes it difficult to process large quantities of sample. The biological materials can be separated from contaminants more effectively using the particles according to the invention. In particular, inhibitors for certain enzymatic reactions can be removed to a large extent according to the invention.

**[0062]** In the preferred embodiment, the particles according to the invention are added to the lysis mixture. After a suitable period of time for adsorption to take place — which can be optimized by mechanical agitation — the particles are separated from the surrounding fluid that contains additional cell components that are not to be detected. This is performed preferably by applying a magnetic field by placing a magnet against the vessel wall.

**[0063]** To remove any contaminants that may still be present, a wash step is preferably performed with a fluid that does not cause the nucleic acids to be determined to be released from the glass surface. An elution buffer having reagent conditions under which the nucleic acids separate from the glass surface is added to remove the nucleic acids from the glass surface. These conditions are low salt conditions in particular. Depending on the intended further use of the nucleic acids, the fluid can now be separated from the particles and processed further. This separation step is preferably performed via application of a magnetic field so that the particles are separated from the eluate.

**[0064]** A preferred embodiment of the present invention is to use the MGPs of the present invention in automatable methods as e.g. described in WO 99/16781. Automatable method means that the steps of the method are suitable to be carried out with an apparatus or machine capable of operating with little or no external control or influence by a human being. Automatized method means that the steps of the method are carried out with an apparatus or machine capable of operating with little or no external control or influence by a human being. Only the preparation steps for the method may have to be done by hand, e.g. the storage containers have to be filled up and put into place, the choice of the samples has to be done by a human being and further steps known to the expert in the field, e.g. the operation of the controlling computer. The apparatus or machine may e.g. add automatically liquids, mix the samples or carry out incubation steps at specific temperatures. Typically, such a machine or apparatus is a robot controlled by a computer which carries out a program in which the single steps and commands are specified. Preferred automatic methods are those which are carried out in a high-throughput format which means that the methods and the used machine or apparatus are optimized for a high-throughput of samples in a short time.

**[0065]** In another embodiment the MGPs according to the present invention are used in semiautomated process which means that some reaction steps may have to be done manually. In a preferred embodiment of the invention, a suspension containing MGPs according to the present invention is taken from a storage container and partial volumes are added to different reaction vessels. Reaction vessels may be reaction tubes made from plastics eventually in microtitreplate format contain 96 or 384 or more wells where a reaction can be carried out. However, these vessels may be made from other material e.g. from steel.

**[0066]** A preferred embodiment of the invention are purification methods followed by a detection step or purification methods followed by an amplification and detection step. The target nucleic or nucleic acid or nucleic acids of interest may be contained in a matrix of non-target nucleic acids, and may even be a minor component in said mixture of specific nucleic acids. Suitable DNA detection methods are known to the expert in the field and are described in standard textbooks as Sambrook et al.: Molecular Cloning, A Laboratory Manual, 2nd Addition, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY and Ausubel et al.: Current Protocols in Molecular Biology 1987, J. Wiley and Sons, NY. There may be also further purification steps before the DNA detection step is carried out as e.g. a precipitation step. The detection methods may include but are not limited to the binding or intercalating of specific dyes as ethidiumbromide which intercalates into the double-stranded DNA and changes its fluorescence thereafter. The purified DNA may also be separated by electrophoretic methods optionally after a restriction digest and visualized thereafter. There are also probe-based assays which make use of an oligonucleotide hybridisation to specific sequences and following detection of the hybrid. It is also possible to sequence the DNA after further steps known to the expert in the field. Newer methods apply a diversity of DNA sequences to a silicon chip to which specific probes are bound and yield a signal when a complementary sequences bind.

**[0067]** Preferred methods according to the invention are amplification methods as the ligase chain reaction and the polymerase chain reaction which specifically amplify target sequences to detectable amounts. Particularly preferred detection methods are the TaqMan® method disclosed in WO92/02638 and the corresponding US patents US 5,210,015, US 5,804,375, US 5,487,972. This method makes use of the exonuclease activity of a polymerase to generate a signal. In detail, the nucleic acid is detected by a process comprising contacting the sample with an oligonucleotide containing a sequence complementary to a region of the target nucleic acid and a labeled oligonucleotide containing a sequence complementary to a second region of the same target nucleic acid sequence strand, but not including the nucleic acid sequence defined by the first oligonucleotide, to create a mixture of duplexes during hybridization conditions, wherein the duplexes comprise the target nucleic acid annealed to the first oligonucleotide and to the labeled oligonucleotide such that the 3'-end of the first oligonucleotide is adjacent to the 5'-end of the labeled oligonucleotide. Then this mixture is treated with a template-dependent nucleic acid polymerase having a 5' to 3' nuclease activity under conditions sufficient to permit the 5' to 3' nuclease activity of the polymerase to cleave the annealed, labeled oligonucleotide and release labeled fragments; and the signal generated by the hydrolysis of the labeled oligonucleotide is detected and/ or measured. TaqMan® technology eliminates the need for a solid phase bound reaction complex to be formed and made detectable.

**[0068]** In more general terms, a procedure for the purification of biological material followed by a detection step is disclosed wherein the amplification and/ or detection reaction is a homogeneous solution-phase multiplex assay for the simultaneous detection of multiple targets (see examples 7.2).

**[0069]** In another embodiment of the invention, the described purification procedure is combined with a amplification procedure using one of the methods described in the following, preferably the use of blocking oligonucleotides. A problem often associated with amplification especially of low amounts of target nucleic acid is the activity of thermostable polymerases at lower temperatures (room temperature up to 40°C). At this temperature primer oligonucleotides often bind unspecifically to each other or to background nucleic acid and may be extended by the polymerase. This entails a decrease of reaction components as well as to a higher level of background signal and consequently to a decreased sensitivity. It may also lead to false-positive results. In order to avoid unspecific activity of polymerases several approaches have been described, like "hot start"-PCR (Chou et al., 1992, Nucl. Acid Res 20, 1717-1723), covalently modified polymerases (e.g. AmpliTaq Gold, Perkin Elmer) or antibodies (Scalice et al., J Immunol. Methods, 172, 147 - 163, 1994) and oligonucleotides (Dang and Jayasena, JMB 264, 268-278, 1996; US 5,763,173; US 5,693,502). According to the present invention blocking oligonucleotides shall be oligonucleotides which are able to block the active center of the polymerases up to the said temperature. These oligonucleotides may be e.g. an aptamer as described in Example 7.2.2.1.3.

**[0070]** In another embodiment of the invention aptamers (see e.g. in Example 7.2.2.1.3) and/ or modified primers alone (see e.g. in Example 7.2.2.1.3) can be used in an amplification reaction and the detection methods connected thereto. This has advantageous effects and can be considered to be an invention on its own which provides superior results. In a preferred embodiment of the invention the 3'-terminal nucleobase, preferably an adenin is modified with a p-(t-butyl)-benzyl-residue. Further modifications, including those at the 3'-1-position are described in EP 866 071 A2 which is incorporated herein by reference.

**[0071]** In still another embodiment of the invention for the purification of biological material followed by a detection step is disclosed wherein for at least 5 cycles of the polymerase chain reaction, the annealing temperature is less than 8°C, preferably less than 3°C above the dissociation temperature of the polymerase-aptamer complex.

**[0072]** The following examples serve to illustrate the embodiments of the invention.

#### Figure legends:

#### **[0073]**

Figure 1: Flow scheme for the production by sol synthesis & spray drying:

Figure 2: Flow scheme for the preparation of the raw MGPs

Figure 3: Schematic depiction of the spray dryer manufactured by Nubilosa. The details are described in the text under Example 1.3

Figure 4: High resolution scanning electron microscopic image of MGP with Merck pigment BM

Figure 5: High resolution scanning electron microscopic image of MGP with CERAC pigment

Figure 6: High resolution scanning electron microscopic image of MGP with Merck pigment MMB

Figure 7: High resolution scanning electron microscopic image of MGP with Strem pigment

Figure 8: High resolution scanning electron microscopic image of MGP with BASF pigment FA

Figure 9: High resolution scanning electron microscopic image of MGP with BASF pigment CE-HQ

Figure 10: High resolution scanning electron microscopic image of MGP with BASF pigment CE-SU

Figure 11: Influence of the magnetic core pigment or the spray dryer on the RNA isolation (spray dryer: Büchi (B))

or Nubilosa (N))

Figure 12: Influence of the parameter "Spray pressure" on the isolation of DNA or RNA

Figure 13: Influence of different MGP production parameters on the isolation of RNA (spray pressure, (L=air, N=ni-  
trogen), inlet temperature (E) or outlet temperature (A) Figure 14a, b: Sedimentation behaviour of different MGPs  
in different suspension media

Figure 15: HREM-image of sample EJ0096.5R-01; MGP with CERAC pigment

Figure 16: HREM image of EJ0100.5R-01, sprayed at low pressure and high temperature, consisting mainly of  
deformed  $\mu$ -scale particles

## 1 Example 1: Production of the magnetic glass particles

**[0074]** Classically, raw materials like  $\text{SiO}_2$  and alkali- or alkaline earth carbonates ( $\text{Na}_2\text{CO}_3$ ,  $\text{K}_2\text{CO}_3$ ,  $\text{CaCO}_3$ ) are  
molten together






type of reaction:






**[0075]** In most cases, however, a composite matrix of silicate, borate and aluminate is used, i.e. pertinent to the  
matrix constituents,  $\text{SiO}_2$  is partially replaced by  $\text{B}_2\text{O}_3$  and  $\text{Al}_2\text{O}_3$ . Alternatively, glass can be synthesized via sol-gel-  
reaction.


type of reaction:

either acid-catalyzed sol-gel reaction, e.g.





or base-catalyzed, as in our case, e.g.





[0076] Advantage: alcohols are easily evaporated during spray-drying; ideally no recrystallisation of salts on the surface

[0077] Thus, alcoholates are turned into hydroxides, which yield by way of elimination of water the corresponding oxides. These, then, form a 3-dimensional, amorphous glass matrix consisting of  $\text{SiO}_2$  /  $\text{B}_2\text{O}_3$  /  $\text{Al}_2\text{O}_3$ , into which certain metal oxide ingredients are embedded as matrix bond separators, e.g.



[0078] For the experiments described here, the glass component was produced via base-catalyzed sol-gel synthesis. The glass composition used in all experiments was (unless stated otherwise) as follows:

70.67 Mol%  $\text{SiO}_2$ , 14.33 Mol%  $\text{B}_2\text{O}_3$ , 5.00 Mol%  $\text{Al}_2\text{O}_3$ , 4.00 Mol%  $\text{K}_2\text{O}$ , 2.00 Mol%  $\text{CaO}$ , 4.00 Mol%  $\text{ZnO}$  (calculated from the mass of particular educts brought to reaction)

### 1.1 Description of the investigated magnetic pigments

[0079] Different types of magnetic pigments were investigated and are summarized in Table 1.

### 1.2 Production of the coating sol (EJ-composition)

[0080] The educts are added in the following order and amount into the heatable stirring vessel:

Tetraethoxysilane (TEOS)	10700 ml
Triethylborate (TEB)	3305 ml
K-methanolate 25% (W/V) in Methanol	1601 ml
Ethanol	11292 ml
Aluminiumisopropanolate	1385 g
Calcium	54.4 g
Zincacetate	498 g

[0081] The vessel is closed thereafter. The sol is heated to 70 °C and stirred overnight (15 h). The temperature is regulated via a thermosensor which dips into the liquid.

[0082] Then the sol is heated to 90 °C and the alcohol/ water mixture (Ethanol: 3781 ml,  $\text{H}_2\text{O}$ : 1512 ml) is added at a rate of 5000 ml/h. The vessel is cooled to 20 °C after the complete addition of the said mixture.

[0083] The lid is opened and 10249 g magnetic pigment (CERAC) is added under vigorous stirring. The prepared sol is transferred into the spray dryer via a hose.

### 1.3 Spray drying

[0084] The inlet temperature of the spray dryer is regulated to 200 °C. The nozzle pressure is regulated to 6 bar and the nozzle is cooled for 3 min with ethanol. Then the hose is connected to the outlet of the glass container and the pigment-containing sol is pumped at a rate of 110 ml/min to the two fluid nozzle (diameter of the opening: 2 mm; supplier: Nubilosa, Type 1B1VVS1) of the spray dryer via a ultrasound device (200 W). The spray drying system is shown schematically in Figure 3. The particles which are formed in the first two minutes are discarded. After the complete spraying of the sol the container under the cyclone (AVO, see Figure 3) with the particles will be taken and the particles will be further treated as described in the next steps.

[0085] The pigment containing sol is stirred in the stirring vessel to prevent sedimentation of the suspended particles. The sol is transferred from the vessel to the nozzle using a pump (SP). Nitrogen heated by an electric heater (EWT) is used as drying gas. The coated pigment is transferred from the drying chamber (T) to the cyclone (ZY). The dried powder can be removed from the container (AVO) under the cyclone. Very fine particles are removed by a filter (SF) from the nitrogen. The spray dryer is used with overpressure to prevent an air intake into the dryer. The gas flow is produced by gas blower (AV).

### 1.4 Further processing of the spray-dried powder

[0086] The powder is transferred into a ceramics bowl and heated in an furnace to 200 °C at a heating rate of 1 K/min. Then temperature is held at 200 °C for one hour and the oven is cooled to room temperature afterwards. The bowl is transferred to an atmosphere furnace with a volume of 27 l which is rinsed with 60 l nitrogen per hour. The furnace is heated to 750 °C with a heating rate of 1 K/min and is held at that temperature for 1 hour. Then the furnace is cooled to 150 °C and rinsed with 60 l air per hour. The furnace is heated to 200 °C with a heating rate of 2 K/min and is held at that temperature for 1 hour and is cooled to temperature afterwards. The powder is transferred to a sieve (50 µm) and sieved for 30 min. Afterwards, the sieved sample is bottled in glass containers, which are sterilized unclosed in an oven which is heated to 200 °C with a heating rate of 1 K/min, held at that temperature for 4 h and then cooled to 80 °C. Then the glass vessels are taken from the furnace, covered with sterile foil and closed with a lid.

[0087] A summary of the important process parameters is presented in Table 2 and Table 3, the produced individual samples with some data are provided in Table 3. Each sample has a specific code. The first two letters describe the used glass chemistry (see below) and the next four numbers encode the production process (see Table 2). The number after the describes the used pigment (see Table 1). The letter R means that the fine content has not been removed, whereas E means that the fine content has been removed with ethanol. The last two numbers describe the number of the lot. The composition of the glass (code EJ) as calculated from the quantity of the educts was 70.67 Mol% SiO<sub>2</sub>, 14.33 Mol% B<sub>2</sub>O<sub>3</sub>, 5.00 Mol% Al<sub>2</sub>O<sub>3</sub>, 4.00 Mol% K<sub>2</sub>O, 2.00 Mol% CaO, 4.00 Mol% ZnO. The composition of the glass (code RN) was 74 Mol% SiO<sub>2</sub>, 15 Mol% B<sub>2</sub>O<sub>3</sub>, 5.00 Mol% Al<sub>2</sub>O<sub>3</sub>, 4.00 Mol% K<sub>2</sub>O, 2.00 Mol% CaO. The composition of the glass (code EP) was 73.61 Mol% SiO<sub>2</sub>, 14.93 Mol% B<sub>2</sub>O<sub>3</sub>, 5.21 Mol% Al<sub>2</sub>O<sub>3</sub>, 4.17 Mol% K<sub>2</sub>O, 2.08 Mol% CaO.

## 2 Example 2: High resolution scanning electron microscopy

[0088] To obtain information about the surface, size and form of the MGP, we carried out investigations with a high resolution scanning electron microscope manufactured by the company JEOL (JSM). The samples were spread onto the sample holder with an electrically conducting double-sided adhesive and sputtered with gold for 36 s with a current of 30 mA. For the imaging of the surface, the emitted secondary electrons (topography) as well as the back-scattered electrons (order number contrast) were viewed. The used primary electron voltage was 10 kV (secondary electrons) or 25 kV (back-scattered electrons).

[0089] The Figure 4 shows MGPs with mica covered with ferric oxide as magnet pigment (BM). The fissure in the glass shell can be clearly seen which stem from the spray drying of the particles when the layer starts to shrink on a non-shrinking substrate (drying fissures). Further more a greater number of spheric particles can be seen which do not contain one of the bigger magnet particles (10 - 60 µm). These spheres without magnetic core (non-magnetic fine content) cannot be removed in a magnetic field, may be transferred into the PCR reaction and will interfere with this reaction.

[0090] The particles with CERAC pigment (see Figure 5) do not have fissure, as the magnet pigment (23 nm average particle size) does not cause tension forces in the layer so that no fissures are created during the spray drying process. Furthermore, the small CERAC-particles are also incorporated in the fine content so that there are no non-magnetic particles contained therein. The particles are also substantially smaller than the particles with mica which can be observed in these figures with the same magnification. MGPs with the other magnetic pigments are shown at the same magnification in Figure 6 to Figure 10.

### 3 Example 3: Physical investigations of the MGPs

[0091] To allow an evaluation of the MGPs before the actual functional tests, in addition the HREM investigations further physical measurements were done with the MGPs. It was interesting to learn about the iron solubility in water, the magnetic force, the fine content and the density. In the following the experiments are described and the results presented.

#### 3.1 Extinction measurements

[0092] To test whether the fines have been removed, 1000 mg of the temperature-treated and sieved powder, are weighed into a 50 ml centrifugation tube (Sarstedt), 40 ml water added and dispersed by shaking. Then, the tube is dipped into a ultrasonic bath (Sonorex (RK 102H; 120/240W) with the total filling height and is put into a magnetic separator (Roche Diagnostics GmbH RD Art.Nr. 1858 025). After 3.5 min magnetic separation, liquid is taken from the vessel with a pasteur glass pipette in the height of the 15 ml mark at the opposite side of the magnet and filled into a 5 mm quartz cuvette (Type 110-QS, Hellma). The extinction of the supernatant is measured in an UV-VISNIR spectrometer (Hitachi U-3000) against a corresponding cuvette filled with deionized water. The measuring range was 200 to 1100 nm in steps of 1 nm to investigate this wavelength range for the absorption bands of eventual impurities. The extinction at a wavelength of 280 nm and 400 nm was taken as a reference.

#### 3.2 Density measurements

[0093] For the density measurements a gas pycnometer (AccuPyc 1330, Fa. Micromeritics) is used. Helium 6.0 is used as gas. The device is calibrated with the supplied standard (steel beads with known volume). Further, the sample is dried for at least 1 hour at 150 °C and then filled into the measurement container and weighed. After the measuring container is put into the gas pycnometer, 10 washing cycles and 5 measuring cycles are used to determine the average value and the standard deviation.

#### 3.3 Determination of the iron solubility

[0094] The iron solubility of the coated and temperature-treated samples is determined with Inductive Coupled Plasma - Atomic Emission Spectroscopy (JY 24, company ISA). Therefor, 1 g of the sample is transferred into a 50 ml polypropylene-tube, filled up with distilled water and kept at a temperature of 60 °C for 20 hours. Then, the samples are filtrated with a 0.2 µm syringe filter and the filtrate is measured. Four single determinations are carried out at a wavelength of 259,940 nm and an average value is computed therefrom.

#### 3.4 Measurement of the magnetic force

[0095] For the measurement of the magnetic force a PP-weighing tube (Company Licefa, Art. Nr. V2-3) completely filled with MGPs is weighed. With the help of a stencil, this sample container is placed in the middle of LDPE tube (Company Kartell, TS 735) burdened with brass so that the lid of the tube can be still closed. The vessel is positioned in the middle of a balance (detection accuracy 0.1 g) with the help of another stencil. After the equalization of the balance, a plastics cap which contains an cylinder-shaped magnet (diameter: 30 mm; height: 113.5 mm; material: samarium-cobalt 2/17) is positioned above the scale.

[0096] Thereby, the MGPs in the scale are attracted against to the gravity thereby decreasing their weight. After the adjustment of the equilibrium (1.5 min) the weight loss of the sample is determined and the value is normalized for 250 mg MGP.

#### 3.5 Results

[0097] The results of the physical characterization of the MGPs with EJ composition and different pigments are summarized in Table 3. It is noticeable that the extinction values are very low when CERAC pigment is used. This can be explained by the lack of non-magnetic fine content because the small CERAC pigment (23 nm) can be incorporated into each magnetic glass particle. The density of the CERAC-MGPs is not very high. This has a positive influence on the sedimentation velocity. The magnetic force is subjected to high fluctuations, however, it is positively influenced by the use of CERAC-pigments. The CERAC-MGPs have a comparatively high leak of iron to the water. However, even ten-fold higher values did not show any effect on the PCR process. In summary, it can be said that the physical properties do not have any significant differences between the different pigments but the CERAC-MGPs have a very low fine content.



#### 4 Example 4: Influence of the magnetic core pigment and of the spray dryer on the BET surface

[0098] The surfaces were determined using a device from Micromeritics (Type ASAP 2400). The measurement was performed at liquid nitrogen temperature. Nitrogen 5.0 was used as measuring gas and Helium 4.6 was used as inert gas. Typically, 5 g of sample was used for one measurement.

[0099] The surface of the MGPs plays an obvious role for the isolation of DNA and RNA. The higher the surface the more DNA can be bound by the same mass of MGPs. It is also possible to use less MGPs and obtain the same performance. This has the effect that the intergrain volume is less which means that less alcohol may be introduced as contaminant into the PCR reaction. The data for the measured BET-surfaces for some samples are summarized in Table 4. When the surfaces of the samples produced on the big spray dryer are compared, it should be noted that the samples with small pigments (BASF FA, STREM and CERAC) have relatively high surfaces, whereas the big Merck pigments have small surfaces. This may be caused by the fact that big magnetic particles cause big MGPs whereas the small magnetic particles are incorporated into the spherical droplets during the spray drying process and have therefore similar surfaces under similar spraying conditions. The BASF CE-SU particles have a size distribution in between the small (BASF FA, STREM and CERAC) and the big Merck particles. In contrast to the Merck particles, they do not possess a structured surface so that these particles have a very smooth glass surface. This results into a smaller surface. A higher pressure was used with the smaller spray dryer and the nozzle of this spray dryer is remarkably smaller than that of the bigger spray dryer. This causes smaller particles whereby the surface increases remarkably. This is in good agreement with the results of Example 5.2.1

[0100] Any influence of the magnetic pigment or the spraying pressure on the results of further physical investigations cannot be recognized except the above-mentioned influence on the fissure formation and the fine content. However, only the measurements of the surface show a direct connection to the results of the functional investigations. Other physical investigation results do not show this direct correlation.

#### 5 Example 5: Binding studies via radio tracing

[0101] There are several methods for the evaluation of MGPs with regard to their suitability for the extraction of nucleic acids. The determination of the extinction at 260 nm before and after the purification is not very sensitive and does not resemble the situation when small amounts of target nucleic acid are extracted from clinical material. The results of functional evaluation methods which rely upon a method for the amplification of nucleic acids, as e.g. by PCR, RT-PCR, NASBA or anything similar, are often not enough convincing. Furthermore, these methods, which are suitable for the determination of a small number of copies of the target genome, are susceptible to disturbances by substances from the sample material or from the sample preparation process. Radioactive binding studies are a suitable analytical method which makes it possible to analyze the sample preparation process step by step. The performance data are no absolute data but are always relative to the performance of a reference particle

##### 5.1 Experimental Protocol

[0102] At first, radioactively labelled DNA or RNA is synthesized enzymatically in a PCR or in vitro transcription process in the presence of  $^{32}\text{P}$ -marked desoxynucleoside or nucleoside-triphosphates. Then, the marked DNA or RNA is separated from the free nucleoside-triphosphates, the content determined and a defined dilution is prepared.

[0103] A small amount of marked DNA or RNA is added to each sample before the examination. During sample preparation, all nucleic acids bind to the MGPs in the presence of chaotropic agents. The MGPs are pelleted by the exertion of magnetic forces and the supernatants can be discarded. The pellet is washed and the bound nucleic acids are eluted at elevated temperature by the reversal of the reaction conditions, i.e. by the addition of a low salt elution buffer. After the binding and an optionally after the washing step, an aliquot of the particle supernatant is spotted onto a filter. The eluate as well as the in water redispersed MGP are spotted onto a filter as well and dried thereafter. At last, the filters are measured in a Beta.Counter and for each sample preparation a distribution is calculated.

##### 5.1.1 Preparation of radioactively labelled DNA

###### 5.1.1.1 A.1.1. Reagents

[0104]

- Expand High Fidelity PCR System (Roche Molecular Biochemicals Cat. No. 732641)
- dNTP Mix (Roche Molecular Biochemicals Cat. No. 1277049)
- Deoxycytidine 5'-alpha-P32 Triphosphate dCTP 3000 Ci/mmol (Amersham Cat. No. PB 10205)

## EP 1 154 443 A1

- lambda-DNA (Roche Cat. No. 1029053) concentration 1ng/ml
- Radiotracer primer 1 (SEQ ID NO 1) concentration 5,3 OD<sub>260</sub> / ml Radiotracer primer 2 (SEQ ID NO 2) concentration 5,2 OD<sub>260</sub> / ml
- QIA Quick PCR Purification Kit (Qiagen Cat. No. 28104)

### 5.1.1.2 Reaction

#### [0105]

- 29.5µl double distilled water
- 5µl Expand High Fidelity Buffer
- 2.5µl dNTP Mix (1:10) diluted with double distilled water
- 1µl Radiotracer primer 1 (SEQ ID NO 1)
- 1µl Radiotracer primer 2 (SEQ ID NO 2)
- 0.3µl <sup>32</sup>P-dCTP
- 10µl lambda-DNA
- 0.75µl Expand High Fidelity -Enzyme Mix

### 5.1.1.3 Amplification

#### [0106]

- 2 min. 94°C
- 10 cycles (10 sec. 94°C / 30 sec. 60°C / 60 sec. 72°C)
- 20 cycles (10 sec. 94°C / 30 sec. 60°C / 60 sec. 72°C + 10 sec. 72°C extension per cycle)
- 7 min 72°C
- 4°C

### 5.1.1.4 Purification

#### [0107]

- according to the QIA Quick PCR Purification Protocol (Qiagen)

### 5.1.1.5 Dilution

[0108] Dilution of DNA 1:10 in double distilled water and measurement in the Beta-Counter

### 5.1.2 A.2. Preparation of radioactively labelled RNA

#### 5.1.2.1 Reagents

#### [0109]

- SP6 / T7 Transcription Kit (Roche Molecular Biochemicals Cat. No. 999644)
- Uridine 5'-alpha-P32 Triphosphate UTP 3000 Ci/mmol (Amersham Cat. No. PB 10203)
- Plasmid pKBH10S, linearized with EcoRI at 100µg/ml
- High Pure RNA Isolation Kit (Roche Molecular Biochemicals Cat. No. 1828665)

#### 5.1.2.2 - Reaction

#### [0110]

- 2µl 10x buffer
- 3µl NTP Mix (AGC)
- 1µl UTP (1:50 with double distilled water)
- 5µl <sup>32</sup>P-UTP
- 7µl linearized plasmid

## EP 1 154 443 A1

- 1µl RNase Inhibitor (Roche Molecular Biochemicals Cat. No. 802808)
- 1µl T7 RNA-Polymerase

### 5.1.2.3 Transcription and DNase-digest

#### [0111]

- 20 min incubation at 37°C
- Addition of 2 µl DNase, RNase free
- 10 min incubation at 37°C
- Addition of 178 µl double distilled water

### 5.1.2.4 - Purification

#### [0112]

- according to the High Pure RNA Isolation Protocol (Roche Molecular Biochemicals)

### 5.1.2.5 -Dilution:

[0113] Dilution of RNA 1:30 in double distilled water and measurement at the Beta-Counter

### 5.1.3 - Radioactive sample preparation

#### 5.1.3.1 - Reagents

#### [0114]

- negative plasma
- Proteinase K concentration 20mg/ml (e.g. Roche Id.Nr. 1942387)
- Poly-A-RNA (e.g. Roche Id.Nr. 108626) concentration 1mg/ml; diluted 1:1000 (volume/ volume ratio) with lysis buffer
- lysis buffer (50mM Tris pH 7.0, 15% (v/v) Polydocanol, 5M Guanidiniumisothiocyanate, 1mM DTT)
- MGP (with glass composition EJ and different core pigments (BM, MMB, CERAC, STREM, BASF-FA, BASF-CE)) suspended in isopropanol at 60mg/ml or at 6mg/ml
- Washing buffer (20mM Tris pH 7.5, 20mM NaCl, 70% (v/v) Ethanol)
- Elution solution: double distilled water
- Auxiliary material: Whatman GF/D Filter

#### 5.1.3.2 - Reaction (1.5 ml protocol)

#### [0115]

- 80µl Proteinase K
- add 410µl negative plasma and mix
- add 500µl lysis buffer and mix
- add 10µl radioactive labelled DNA or RNA and mix
- 10 min incubation at room temperature under shaking
- add 500µl MGP suspension (concentration 6mg/ml) and mix
- 20 min. incubation at room temperature under shaking
- separation for 2 min in Magnetic separator (Dyna)
- discard supernatant and spot 300µl onto a filter
- add 750µl wash buffer, vortex, 2min separation
- discard supernatant, eventually spot 375µl supernatant onto a filter
- repeat washing procedure twice
- add 100µl elution solution, incubate 5 min. at 80°C in a thermomixer
- separate 2 min in a magnet holder, spot supernatant onto a filter
- add 100µl elution solution, resuspend and spot MGPs onto a filter

- dry filters for 60 min at 75°C in a drying oven
- transfer filter into scintillation tubes, add 5ml scintillation solution and measure in the beta-counter

### 5.1.3.3 - Experimental Protocol (1ml protocol)

[0116]

- 25µl Proteinase K
- add 415µl negative plasma and mix
- add 500µl lysis buffer and mix
- add 10µl radioactive labelled DNA or RNA and mix
- 5 min incubation at room temperature under shaking
- add 50µl MGP suspension (concentration 60 mg/ml) and mix
- 20 min. incubation at room temperature under shaking
- separation for 2 min in the magnetic separator (Dyna)
- discard supernatant and spot 300µl onto a filter
- add 700µl wash buffer, vortex, 2min separation
- discard supernatant, eventually spot 350µl supernatant onto a filter
- repeat washing procedure twice
- add 120µl elution solution, incubate 10 min. at 80°C in a thermomixer
- separate 2 min in a magnet holder, spot supernatant onto a filter
- add 100µl elution solution, resuspend and spot MGPs onto a filter
- dry filters for 60 min at 75°C in a drying oven
- transfer filter into scintillation tubes, add 5ml scintillation solution and measure in the beta-counter

## 5.2 Results of the radiotracing experiments:

### 5.2.1 Influence of the magnetic core pigment or the spray dryer on the RNA isolation

[0117] Different MGP-types, which were produced using EJ glass chemistry and various cores in the nano- or mikro-range (MMB, CERAC, etc.) on different spray dryers (Büchi or Nubilosä), were characterized with regard to their behaviour at the nucleic acid extraction from virus-negative pool material with the radiotracing method according to Example 5.1.3.2. The RNA parameter proved to be the most sensitive in the course of the studies and was therefore chosen as parameter. Figure 11 shows BASF-CE is not suitable as core material because only small amounts of the bound RNA can be found in the eluate. The EJ/ CERAC particles which were sprayed in the Büchi system at 6 bar showed the performance of the reference EJ/ MMB which were sprayed in the Nubilosä system.

### 5.2.2 Influence of the parameter spray pressure on the isolation of DNA or RNA

[0118] Different MGP types produced with the Nubilosä system with different spraying pressures are compared according to 5.1.3.3. The reference particles are EJ /MMB MGP. The DNA and RNA binding properties are investigated. Whereas the DNA parameter shows no dependence from the spraying pressure, the RNA parameter shows significant performance differences. The performance of the EJ/ CERAC particles produced with 1.5 bar spraying pressure with the Nubilosä system is lower than that of the reference. There is a lower performance in the series in dependence of the spraying pressure which varied from 1.5 to 3.4 bar (~30%). Particles which are sprayed with 4.3 bar reached 90 % of the performance of the particles which are sprayed at 1.5 bar (see Figure 12).

[0119] The experiments prove the direct connection between the process parameters for the production of the MGPs and of the performance in the test. It should be noted that an increase in the spraying pressure leads to a lower test performance but, beginning from a certain spraying pressure, the particle properties are improved leading to a better performance.

### 5.2.3 Influence of different MGP production parameters on the isolation of RNA and DNA

[0120] These experiments should lead to the result whether a variation of the spraying pressure leads to MGPs with even better performance.

[0121] Therefore, MGPs are produced on the Nubilosä system at a pressure of 1.5 bar, 4.3 bar and 6 bar using nitrogen as spraying gas.

[0122] In order to obtain a careful drying process, inlet and outlet temperature of the spray dryer are additionally

decreased. The influence of these factors on the RNA isolation is investigated according to 5.1.3.3. using EJ / MMB MGP as reference.

[0123] The results (see Figure 13) show the surprising effect of a dramatic performance reduction which is caused by the decrease of the spraying temperature and could not be foreseen. It was possible to reach the performance of the reference quality by the increase of the spraying pressure. Concomitant with the superior suspension stability, these particles are therefore superior to the reference.

## 6 Example 6: Sedimentation analytics of the magnetic glass particles

### 6.1 Experimental protocol

[0124] An Uvikon Spectrophotometer Model 930 produced by Kontron Instruments is used for the evaluation of the sedimentation behaviour of the magnetic glass particles. This spectrophotometer is modified to allow variable adjustment of the cuvette along a scale bar. For the measurements the cuvette is set at a position in which the measuring beam with a wavelength of 650 nm traverses the cuvette at a position which is at 2/3 of the filling height (scale position 7.5). Macro cuvettes made from polystyrene are used which have a volume of 4 ml and a path length of 1 cm. Prior to measurements, calibration is made in a one beam procedure against pure suspension medium. The MGP samples are dispersed to homogeneity in suspension medium, typically at a mass/volume ratio of 3 mg/ml, and measured immediately. The change of the extinction with time is monitored continuously at the said wavelength of 650 nm.

[0125] The physical quantity used for the comparison of the sedimentation velocity of different samples is the half life ( $t_{1/2}$ ) in a particular suspension medium. This is the period of time until the extinction of the suspension in the upper third of the cuvette is half the value at the beginning of the measurement. The decline of extinction is caused by the sedimentation of the particles and the concomitant clearance of the upper third of test volume.

[0126] The above-described device further allows the installation of a magnet beneath the cuvette. Thereby the velocity of the magnetic separation can be determined.

### 6.2 Results of the sedimentation analytics

#### 6.2.1 Experiment 1:

[0127] Several MGP-types with different cores in the range of nano- or micrometers and produced with EJ glass chemistry are investigated spectrophotometrically for their sedimentation and separation behaviour, i.e. with and without magnet under the cuvette. Mass/volume is 6 mg/ml in this case. The suspension medium is a 1:1 mixture of isopropanol and lysis buffer. The results are summarized in . The particles from the CERAC type show a clear advantage in the stability of the suspension but no disadvantages for the magnetic separation. (See also Figure 14).

#### 6.2.2 Experiment 2:

[0128] The sedimentation behaviour of different MGPs from the type CERAC produced with EJ glass chemistry are investigated in pure isopropanol.

[0129] Important production parameters

EJ0100.5R-01 - 1.5 bar spraying pressure, 230°C inlet temperature, Nubiosa system

EJ0108.5R-01 - 4.3 bar spraying pressure, 230°C inlet temperature, Nubiosa system

EJ0096.5R-01 - 6.0 bar spraying pressure, 150 °C inlet temperature, Büchi system

EJ0096.5R-01 is shown in Figure 15. These beads are largely spherical, with a highly structured surface and a size of predominantly 0.5-5 µm. The sample EJ0100.5R-01, sprayed at low pressure and high temperature, consists mainly of deformed µ-scale particles (see Figure 16, which shows a functional equivalent to EJ0100.5R). In conclusion, particles like EJ0096.5R-01 show significant retardation of sedimentation, which is most advantageous for liquid transfers of MGP suspensions (see Figure 14b). The results are summarized in

## 7 Example 7: Functional test with PCR

**7.1 Heterogeneous functional assays: amplification with PCR on a Perkin Elmer GeneAmp 9600® and detection with a biospecific binding test with a chemiluminescent-marked detection probe on a modified Elecsys1010®**

### 7.1.1 General considerations

**[0130]** Virus particles in the sample (e.g. plasma) are lysed in the presence of protease and high concentrations of chaotropic salt as well as detergent. Then, the particulate adsorbent (= MGP) is added for physico-chemical adsorption of released nucleic acids onto the glass surface, followed by magnetic separation and washing of the loaded beads, i.e. bound/free separation. Finally, dissociation of bound nucleic acids from the beads (= elution) is conducted under reversed reaction conditions relative to adsorption, i.e. with low salt buffer or even distilled water. An aliquot of eluate is then mixed with an aliquot of PCR mastermix to start amplification of the nucleic acids recovered in the eluate. This reaction is characterized by the equation

$$N_i = N_0 \times (1+E)^n, \text{ with}$$

$N_0$  = number of molecules at the start of the polymerase chain reaction

$N_i$  = number of molecules at the end of polymerase chain reaction

$E$  = efficiency of amplification =  $0 \leq E \leq 1$

$n$  = number of reaction cycles = typically  $20 \leq n \leq 35$

**[0131]** After PCR with at least one biotinylated primer, an aliquot of biotin-tagged amplificate is mixed with hybridization buffer and detection probe. After incubation, streptavidin-coated beads are added, followed by another incubation. Finally the beads are washed, signal buffer is added and the chemiluminescent signal intensity measured, which is correlated with the mass of amplified nucleic acid bound and, thus, the viral load of the plasma sample.

**[0132]** The expert in the field may also carry out the 1 ml protocol manually.

### 7.1.2 Experimental Protocol

#### 7.1.2.1 Reagents

##### 7.1.2.1.1 Sample preparation

**[0133]** Proteinase K, liquid in glycerol/Ca-acetate, 20 mg/ml

**[0134]** Poly-A-RNA, 1 mg/ml, use level is a 1:1000 dilution in lysis buffer lysis buffer, consisting of:

- Tris-buffer, 50 mmol/l, pH 7.0 (1.0 & extractor protocol, respectively) or 4.0 (1.5 ml protocol)
- Polydocanol, 15% (v/v) (1.0 & extractor protocol, respectively) or Triton X-100 20% (v/v) (1.5 ml protocol)
- Guanidinium-isothiocyanate, 5 mol/l
- 1 mmol/l DTT

- magnetic glass particles (MGP) either of the type EJ/BM, EJ/MMB oder EJ/CERAC suspended in isopropanol (99,8% purity) at 60 mg/ml
- wash buffer consisting of

- Tris-Puffer, 20 mmol/l, pH 7.5
- 60% Ethanol / aq (1.0 & extractor protocol, respectively) or 70 % (1.5 ml protocol)
- NaCl, 20 mmol/l

Eluent = double distilled water

**[0135]** Amplification/ Mastermix:

- PCR-buffer, consisting of buffer medium

RT-PCR (Human immunodeficiency virus (HIV), Hepatitis C Virus (HCV)): 250 mmol/l Bicine/KOH pH 8,2, 557 mmol/l K-Acetate, 40% Glycerol

HBV-PCR (Hepatitis B virus (HBV)): 20 mmol/l Tris-HCl pH 8,3; 100 mmol/l KCl, 0,012% Brij 35 (= 2 x-concentrate)

Metal cations,  $MgCl_2$  (HBV-PCR) 3 mmol/l or  $MnCl_2$ , (RT-PCR) 2.5 mmol/l (HCV) and 1,25 mmol/l (HIV)

Deoxynucleoside-triphosphate (dATP, dGTP, dCTP, dTTP, dUTP)

## EP 1 154 443 A1

Analyte-specific forward-primer

Analyte-specific reverse-primer

Uracil-N-glycosidase (UNG)

DNA-polymerase (Taq- or Tth-polymerase for HBV or HIV/HCV, respectively) H<sub>2</sub>O-demineralised (molecular biology grade) for volume adjustment ad 100 µl

**[0136]** Stop-reagent for UNG after the amplification

- N-lauroylsarcosine (e.g. Roche Id.Nr. 133895), 1% w/v; 5 µl per 100 µl amplificate

### 7.1.2.1.2 Detection

**[0137]**

Hybridisation buffer (e.g. Roche Id.Nr. 1930273)

chemiluminescence-marked detection probes:

HCV (Roche BMO 28.140336), working stock = 8,0 nmol/l

HIV (Roche BMO 28.540948), working stock = 7,8 nmol/l

HBV (Roche BMO 28.540917), working stock = 9,2 nmol/l

SA-covered ECL-Beads (e.g. Roche Id.Nr. 1865943-001)

denaturation solution (e.g. Roche Id.Nr. 1930257)

ProCell (e.g. Roche Id.Nr. 1717685)

CleanCell (e.g. Roche Id.Nr. 1717642)

### 7.1.2.1.3 Primers and probes

**[0138]** Primer:

HIV-forward: SEQ ID NO 3

HIV-reverse: SEQ ID NO 4

HCV-forward: SEQ ID NO 5

HCV-reverse: SEQ ID NO 6

HBV-forward: SEQ ID NO 7

HBV-reverse: SEQ ID NO 8

**[0139]** Detection probes:

HIV: SEQ ID NO 9

HCV: SEQ ID NO 10

HBV: SEQ ID NO 11

## 7.1.2.2 Reaction conditions &amp; test procedure

Sample preparation:

- 5 ➤ 1.0 ml manual protocol; => used for Experiment 1 see Example 7.3.1

**[0140]**

- 10 add 25 µl of proteinase K to 425 µl of plasma sample, vortex,  
add 500 µl of lysis buffer, incubate 5 min at room temperature with mechanical agitation (1300 rpm in Eppendorf mixer),  
add 50 µl of MGP suspended in isopropanol (concentration 60 mg/ml), vortex, and incubate 20 min at room temperature on a roller mixer,  
magnetic separation using a Dynal magnetic separator (2 min);  
15 remove unbound fraction through aspiration, and add 700 µl wash buffer, vortex, separate, aspire;  
repeat wash procedure another 4 times,  
add 120 µl of DEPC-water, vortex, and elute 10 min at 80°C in an Eppendorf Thermomixer at 1300 rpm with cups uncapped,  
separate beads from aqueous supernatant (= eluate) with Dynal magnetic separator (2 min),  
20 freeze eluate until further use.

- automated protocol on in-house-built extractor; => used for Experiment 2 and 3 (see Example 7.3.2 and Example 7.3.3)

- 25 **[0141]** Basically the same procedure and reagent set as above. Additionally, an amount RNA internal control (IC, see below) is spiked into each and every sample, the extraction process is thermostated at ca. 40°C, and volumes are adjusted to 2 ml total volume of lysis mix, i.e.

- 30 50 µl IC  
50 µl proteinase K  
850 µl sample  
1000 µl lysis buffer  
100 µl MGP suspension  
2200 µl wash buffer for 5 wash steps each  
35 125 µl eluent

- 1.5 ml manual protocol; => used for Experiment 4 (see Example 7.3.4)

**[0142]**

- 40 add 80 µl of proteinase K to 420 µl of plasma sample, vortex,  
add 500 µl of lysis buffer, incubate 10 min at room temperature with mechanical agitation (1300 rpm in Eppendorf mixer),  
add 500 µl of MGP suspended in isopropanol (concentration 6 mg/ml), vortex, and incubate 20 min at room temperature on a roller mixer,  
45 magnetic separation using a Dynal magnetic separator (2 min);  
remove unbound fraction through aspiration, and add 700 µl wash buffer, vortex, separate, aspire;  
repeat wash procedure another 4 times,  
add 100 µl of DEPC-water, close the cups, vortex, and elute 15 min at 80°C in an Eppendorf Thermomixer at  
50 1300 rpm,  
separate beads from aqueous supernatant (= eluate) with Dynal magnetic separator (2 min),  
freeze eluate until further use.

55



# EP 1 154 443 A1

amplification

total reaction volume = 100 µl for all assays

5 **HBV**: eluate volume for PCR = 20 µl

[0143]

	stock solution	end concentration in PCR / µl
Water ( PCR-Grade )		4 µl
DNA-Masternix	2-x	1-x / 50 µl
MgCl <sub>2</sub>	25 mM	3.0mM / 12µl
Primer SEQ ID NO 7	5 µM	0.2 µM / 4µl
Primer SEQ ID NO 8	5 µM	0.4 µM / 8 µl
UNG	1U/µl	2 U / 2 µl

**HCV**: eluate volume for PCR = 40 µl

[0144]

	stock solution	end concentration in PCR / µl
Water ( PCR-Grade)		18 µl
Bicine-Buffer RT 5x	5-x	1-x/ 20 µl
MnOAc	25 mM	2.5mM / 10µl
dNTP-Mix (dUTP/	30 mM	0.6mM
dATP/dCTP/dGTP)	10 mM	0.2mM/ 2 ul
Primer SEQ ID NO 5	10 µM	300 nM/ 3 µl
Primer SEQ ID NO 6	10 µM	300 nM/ 3 µl
UNG	1 U/µl	2 U / 2 µl
Tth-Polymerase	5.5 U/µl	10 U / 2 µl

**HIV**: eluate volume for PCR = 40 µl

[0145]

	stock solution		end concentration in PCR / µl
Water ( PCR-Grade )			20 µl
Bicine-Buffer RT 5x	5-x	1-x/ 20 µl	
MnOAc	25 mM	1.25mM / 5µl	
dNTP-Mix (dUTP/			
dATP/dCTP/dGTP)	10 mM	0.2mM/ 2 µl	
Primer SEQ ID NO 3	5 µM		0.2 µM / 4 µl
Primer SEQ ID NO 4	5 µM		0.2 µM / 4 µl
UNG	1 U/µl	2 U / 2 µl	
Tth-Polymerase	5.5 U/µl	15 U / 3 µl	

[0146] After PCR, UNG is blocked through the addition of laurylsarcosin concentration 1% use level.

[0147] Thermocycling profiles are as follows:

<b>HBV</b>	UNG-step	1x	10 min	37°C
	PCR	35x	30 sec	92°C
			30 sec	55°C
			40 sec	72°C

(continued)

HCV	UNG-step	1x	10 min	37°C
	reverse transcriptase step	1x	30 min	60°C
	denaturation		1 min	95°C
	PCR	2x	10 sec	95°C
			20 sec	60°C
		33x	15 sec	90°C
			20 sec	60°C
			7 min	72°C
	follow-up incubation			
HIV	UNG-step	1x	10 min	37°C
	reverse transcriptase step	1x	30 min	60°C
	PCR	4x	10 sec	95°C
			10 sec	55°C
			10 sec	72°C
		31x	10 sec	95°C
			10 sec	60°C
			10 sec	72°C

detection on modified Elecsys 1010®

[0148]

reagent	volume (HBV, HCV, HIV)	incubation time (HBV, HCV, HIV)
PCR product	10 µl	
denaturation solution	35 µl	5 min
detection probe	120 µl	30 min
SA-beads	35 µl	10 min

## 7.2 Homogeneous functional assays: 5'-nuclease-assay-technology on a Cobas Taqman®

### 7.2.1 General considerations

[0149] Lysis of viral particles as well as adsorption, purification and elution of nucleic acids extracted from the sample are conducted as described above (see Example 7.1.2). Again, amplification of target molecules is described by the equation  $N_i = N_0 \times (1+E)^n$ , with

$N_0$  = number of molecules at the start of the polymerase chain reaction

$N_i$  = number of molecules at the end of polymerase chain reaction

$E$  = efficiency of amplification =  $0 \leq E \leq 1$

$n$  = number of reaction cycles = typically  $40 \leq n \leq 60$  in this case.

[0150] With 5'-nuclease technology, however, amplification and detection reactions, respectively, are closely interwoven, and occur in solution phase, i.e. without solid phase immobilisation and corresponding washing steps (= **homogeneous PCR**). To this end, detection probes with 2 particular chemical modification are added to the PCR mastermix. One of these modifications is a fluorogenic reporter group (R, for instance a derivative of 6-carboxy-fluorescein) covalently attached to the backbone of the probe, the other one is a dye (for instance a polymethine-cyanine derivative) capable of absorbing the fluorescent light of the reporter and to quench it (quencher). The quencher is typically attached to the probe backbone at the 5'-end, whereas the reporter is located within the oligo sequence, spaced from the quencher by a number of nucleotide building blocks. These probes bind to the target nucleic acid (sense or anti-sense strand) close to the 3'-end of a primer (reverse or forward). As soon as primer has annealed to the target and DNA-polymerase gets bound to the primer:target hybrid, elongation starts. Due to the 5'-nuclease activity of the enzyme, simultaneously with copy strand synthesis the probe is cleaved as soon as the polymerase reaches the probe binding site, reporter and quencher get separated and the fluorescent signal becomes measurable. This process is repeated with every cycle, and more and more fluorescent reporter is accumulated in solution until reagent depletion at the end of the

reaction. So, in a signal-over-time plot, sigmoidal growth curves are generated. The bigger  $N_0$ , the earlier the signal curve rises above noise level.

[0151] The point on the time axis, where the fluorescent signal can be significantly distinguished from background signal is called threshold cycle (ct). ct is a measure of assay sensitivity: the smaller the ct-value, the more sensitive is the assay. ct values can be calculated by means of different mathematical operations, for example cut-off approaches (average background signal intensity multiplied by a constant factor yields a cut-off signal intensity to discern negative from positive) or approaches where the location of the maximum of the first differentiation of the signal-over-time curve (i.e. the steepness profile), or the location of the maximum of the second differentiation on the time axis, are computed and defined as ct.

[0152] This amplification / detection technology allows for **real-time monitoring of PCR** and for **closed-tube processing** as well, i.e. in contrast to standard procedures, the PCR tubes remains closed after pipetting eluate and mastermix which effectively reduces contamination risks.

[0153] Moreover, if one uses primer and probe sets for different viral species (and, thus, different analyte molecules and target sequences) combined in one mastermix, it is possible to perform multiple amplification / detection reactions simultaneously, depending on the viral load of the individual under inspection. This is the basis for so-called **multiplex assays**.

[0154] What is more, due to the generic nature of MGP based sample preparation, all nucleic acids present in the sample are extracted by way of physico-chemical adsorption to the particle surface, independent of sequence characteristics. This will also include human DNA (hDNA), released from disrupted blood cells, e.g. leucocytes, the titer of which may differ widely according to the physiological or pathological status of the individual blood sample donor. For instance, in cases of autoimmune diseases like SLE, hDNA levels may be elevated substantially. So, hDNA and one or more pathogenic nucleic acids present in a given sample constitute a mixture of various nucleic acids of different sequence specificities which are co-extracted. They constitute a matrix of polynucleotides that are extracted without discrimination, followed by sequence-specific amplification and detection of target nucleic acids via interaction with specific primers and probes under appropriate reaction conditions.

[0155] Given a pathological level of 4000 ng/ml hDNA in plasma in case of SLE, and a low viral load of 50 copies of viral genomic RNA per ml of plasma, and 10000 nucleotides per genomic RNA. With ca. 325 dalton (1 dalton =  $1,66 \times 10^{-24}$  g) per nucleotide, 50 copies or 500000 nucleotides of target RNA make ca.  $2,7 \times 10^{-7}$  ng per ml of plasma, resulting in a relative abundance of target: non-target nucleic acid of approximately  $1 : 10^{+12}$  ! hat is more, in order to monitor the whole process, an artificial nucleic acid construct may be added to the samples, preferably packaged (armored) in a modified virus particle, which is co-extracted and co-amplified with the natural target. This internal control (IC) features a unique probe binding region for an IC detection probe, which differs from target-specific probes by a different reporter group with distinguishable emission characteristics. Thus, IC signal can be discerned from target signal, and as the IC is known to be present in the sample, it functions as a monitoring agent. So, **multi labeling** expands the utility of multiplex assay technology. The internal control (IC) is described in WO98/00547.

## 7.2.2 Experimental protocol

### 7.2.2.1 Reagents

#### 7.2.2.1.1 Sample preparation

[0156] See above (Example 7.1.2 => automated protocol on in-house-built extractor)

#### 7.2.2.1.2 5'-Nuclease-Assay, reactants & reaction conditions

[0157]

Reagent	Concentration of stock solution	Final concentration in the test	Addition ( $\mu$ l / reaction)
Mn(OAc) <sub>2</sub> pH 6.5	50 mM	3 mM	5.75
dNTPs (dG, dA, dC) (dT) (dU)	100 mM	300 $\mu$ M 50 $\mu$ M 500 $\mu$ M	2.50
DEPC-H <sub>2</sub> O		-	9.50

# EP 1 154 443 A1

(continued)

	Reagent	Concentration of stock solution	Final concentration in the test	Addition (μl / reaction)
5	Glycerol	80%	5,64% in total 2.8% added here *	3.50
	K Oac pH 7.5	2 M	100 mM	5.00
	Tricine pH 8.3	1 M	50 mM	5.00
10	DMSO	80%	5.0%	6.25
	Primer SEQ ID NO 12	50 μM	150 nM	0.30
	Primer SEQ ID NO 13	50 μM	150 nM	0.30
	Primer SEQ ID NO 14	50 μM	400 nM	0.80
	Primer SEQ ID NO 15	50 μM	150 nM	0.30
15	Primer SEQ ID NO 16	50 μM	400 nM	0.80
	Primer SEQ ID NO 17	50 μM	150 nM	0.30
	Primer SEQ ID NO 18	50 μM	150 nM	0.30
	Probe SEQ ID NO 19	50 μM	100 nM	0.20
20	Probe SEQ ID NO 20	50 μM	100 nM	0.20
	Probe SEQ ID NO 21	50 μM	100 nM	0.20
	Probe SEQ ID NO 22	50 μM	100 nM	0.20
	UNG	2.4 U / μl	10 U	4.20
	ZO5	10 U / μl	40 U	4.00
25	Aptamer SEQ ID NO 23	50.4 μM	200 nM	0.40

\* The rest of glycerol is added through the enzymes ZO5 (a mutin of the Tth-DNA-polymerase) and UNG (uracil-N-glycosidase).

[0158] The common multiplex thermocycling profile for all test parameters is as follows:

UNG-step	45°C - 10 min
denaturation	94°C - 30 sec
reverse transcription	58°C - 30 min

PCR	95°C - 20 sec / 59°C - 50 sec 5x
	91°C - 15 sec / 52°C - 50 sec 55x

## 7.2.2.1.3 Sequences

[0159] Primer:

HIV-forward: SEQ ID NO 12  
HIV-forward: SEQ ID NO 13  
HIV-reverse: SEQ ID NO 14

HCV-forward: SEQ ID NO 15  
HCV-reverse: SEQ ID NO 16

HBV-forward: SEQ ID NO 17  
 HBV-reverse: SEQ ID NO 18

**[0160] Probes:**

HIV: SEQ ID NO 19  
 HCV: SEQ ID NO 20  
 HBV: SEQ ID NO 21  
 IC: SEQ ID NO 22

Aptamer: SEQ ID NO 23

**[0161]** Melting temperature of the DNA polymerase-aptamer complex = 51,7 °C (=50 % dissociation)

**Terminology of the chemical derivatisations:**

**[0162]** Some of the oligonucleotides are derivatised with Cy5 which is a Pentamethine-diindocarbocyanine coupled to alkylphosphatidyl-linker (Pharmacia Biotech Cy5-N-ethyl-phosphoramidite) and which functions as quencher (Q);  $\lambda_{EX} = 630 \text{ nm}$ ,  $\lambda_{EM} = 665 \text{ nm}$ . Some of the oligonucleotides are derivatised with FAM which is 6-carboxy-fluorescein coupled to a 2-(amino-cyclohexyl)-propane-1,3-diol-linker (Biogenex CX-FAM-phosphoramidite) and which functions as a reporter for targets (R);  $\lambda_{EX} = 485 \text{ nm}$ ,  $\lambda_{EM} = 515 \text{ nm}$ . Some of the oligonucleotides are derivatised with which is hexachloro-6-carboxy-fluorescein coupled to a 2-(amino-cyclohexyl)-propane-1,3-diol-linker (Biogenex CX-HEX-phosphoramidite) and which functions as reporter for the internal control (R);  $\lambda_{EX} = 530 \text{ nm}$ ,  $\lambda_{EM} = 585 \text{ nm}$

**7.2.2.1.4 Reaction conditions**

**[0163]** The reaction conditions are described in the results of the experiments (see Example 7.3).

**7.2.2.1.5 Other materials**

**[0164]**

- virus-negative plasma (O-Matrix, single plasma or Plasma-Pool), e.g. citrate-plasma or EDTA-plasma
- virus-positive plasma or virus-containing culture supernatants, which can be used to adjust certain virus titers by mixing with O-matrix in appropriate ratios.
- alternatively: in vitro-transcripts with the target-sequences to be investigated
- human placental DNA (a. genomic, Sigma cat. no. D4642; b. fragmented, Sigma cat.no. D3287), added to the samples to simulate pathological conditions which lead to the enhanced release of intracellular substances and thus to enhanced levels of DNA/ RNA in the blood, e.g. auto immune disease as SLE or hemolysis.

**7.3 Results of the functional tests**

**7.3.1 Experiment 1**

**[0165]** Different MGP-samples of the type EJ/CERAC are investigated with the methods described in 7.1. The test variable was the spraying pressure:

EJ0100.5R - 1.5 bar

EJ0106.5R - 2.5 bar

EJ0107.5R - 3.5 bar

EJ0108.5R - 4.3 bar

[0166] It could be demonstrated that with increasing spraying pressure, i.e. shift towards smaller average bead diameter, the unspecific binding (USB) decreases whereas the highly specific signal generation is unchanged which results in elevated signal-to-noise ratios

[0167] The virus titer adjustment 0.5xGG is approximately 100 sgu/ml (sgu = signal generating units) in the case of HBV, and approximately 150 sgu/ml in the case of HIV. The data are summarized in Table 7.

### 7.3.2 Experiment 2:

[0168] Two variants each of the type EJ/MMB and EJ/CERAC, respectively, are functionally compared using the method as described in Example 7.2 in conjunction with multipool (MP) and individual (PL) plasma samples. EJ0047.2R (MMB) and EJ0100.5R (CERAC) are sprayed under standard conditions, i.e. 1.5 bar, 230°C inlet temperature and approximately 110 °C outlet temperature. EJ0102.2R (MMB) and EJ0108.5R (CERAC) are development variants with regard to the spraying conditions (inlet temperature decreased to 200°C [MMB]), and spraying pressure increased to 4.3 bar [CERAC]). The results are summarized in Table 8 and show the potential of the CERAC nano-core particles to obtain higher sensitivity as exemplified by the earlier threshold cycle and/or the larger signal differences (saturation signal minus noise level, S-N).

### 7.3.3 Experiment 3

[0169] Several MGP preparations of the type EJ/MMB and EJ/CERAC (see Table 9) are functionally compared using the method as described in Example 7.2. The results are summarized in Table 10 and show the potential of the of the EJ0096.5R-01-type particles to obtain higher sensitivity as exemplified by the earlier threshold cycle or higher hit rate irrespective of the particular assay.

### 7.3.4 Experiment 4

[0170] Several MGP preparations of the type EJ/MMB and EJ/CERAC are functionally compared using the method as described in Example 7.1 wherein the adsorption incubation is conducted with or without shaking. Thereby, the sedimentation velocity becomes decisive, i.e. the higher the sedimentation velocity the higher the number of particles which are removed from the interaction with the analyte in the forming precipitate. In contrast, if the sedimentation velocity is smaller then time span is longer in which analyte molecules from the liquid may adsorb to the surface of the adsorbent. The results are summarized in Table 11 (EJ0047.2R was used as a reference) show that without mechanical agitation the loss of performance is highest (>40 %) with the MMB-type (differs considerably from the characteristics of this invention), and least, or practically absent, with the CERAC-type (most close to the characteristics of the invention within this series).

[0171] To be able to assess the functionality of the different types of MGP thoroughly, a performance index was calculated for each type in the following way:

- > the eluate of several batches for each type of MGP and each titer level, respectively, are pooled into 1 eluate pool
- > out of each eluate pool, 3 amplifications were performed for each assay (HIV, HCV, HBV)
- > each amplificate was measured in singlicate on the modified Elecsys 1010®
- > signals are averaged for each type of MGP, assay, and titer level
- > signal-to-noise (S/N) factors are calculated for each type of MGP and assay, respectively, i.e. low titer (weakly positive) over O-matrix (negative), and elevated titer over O-matrix
- > S/N factors are normalized to the reference type of MGP at the time
- > calculation of the sum of normalized S/N factors for each type of MGP, cumulated over all assays and titer levels; S/N factors for the low titer range are weighted 2-fold relative to those for the high titer level so as to pronounce sensitivity aspects
- > the resulting sum is assigned performance index for each type of MGP investigated

### 7.3.5 Experiment 5

[0172] Different types of MGP were used to extract HCV *in vitro* transcripts which were diluted to various titer levels in diluent containing 10 mmol/l Tris, pH 8.0, 1 mM EDTA, 20 µg/ml poly-A-RNA and 0.05% NaN<sub>3</sub>, and spiked into pooled

plasma.

[0173] Human background DNA (hBG-DNA) was spiked at 0 or 4000 ng/ml into the sample, respectively. Surprisingly, it is possible to reduce interference by hBG-DNA by way of bead selection, as demonstrated by the data presented in Table 12.

### 7.3.6 Experiment 6

[0174] Various types of MGP were used to process HCV positive plasma samples. Human background DNA (hBG-DNA) was spiked at 0 or 4000 ng/ml into the sample, respectively. Again, a significant impact of bead size and bead geometry is being observed. MGP preparation EJ0096.5R, which represents the MGP quality according to the present invention the most, shows very clearcut advantages both in terms of minimal shift of ct values, and reducing loss of specific signal generation (S-N), as indicated by the data presented in Table 13.

Table 1

Company	Abbreviation	Description	Code (see Example 1.4)
---	---	No pigment	
Merck Darmstadt, Germany	BM	Merck Black Mica: Small plates of mica (support), diameter = 10-60 $\mu\text{m}$ , thickness approximately 1-2 $\mu\text{m}$ , $\text{Fe}_3\text{O}_4$ -ashlars and $\text{TiO}_2$ -grains are attached; typically, several pigment units are aggregated (Merck Iridin®)	0 1
Merck Darmstadt, Germany	MMB	Merck Microna Matte Black Small plates of mica (support), diameter = 3-15 $\mu\text{m}$ , thickness approximately 1-2 $\mu\text{m}$ , $\text{Fe}_3\text{O}_4$ -ashlars are attached; typically, several pigment units are aggregated	2
BASF Ludwigshafen, Germany	BASF-FA	BASF iron oxide FA28-41: Needles in the nanoscale range made from $\gamma\text{-Fe}_2\text{O}_3$ , length approximately 200-400 nm, very high tendency to aggregate to particles in the $\mu$ -scale because of the form and large highly structured surface	4
Cerac, Milwaukee, WI, USA	CERAC	CERAC $\gamma\text{-Fe}_2\text{O}_3$ (Catalogue number I-2012, distributed by Chemco Chemieprodukte GmbH in Germany) $\gamma\text{-Fe}_2\text{O}_3$ -microbeads in the nanoscale (pure ferric oxide), diameter = 23 nm, non-aggregating	5
Strem Chemicals, Newburyport, MA, USA	STREM	STREM $\text{Fe}_3\text{O}_4$ >95% (Catalogue-No.: 93-2616) Microbeads in the nanoscale range made from precipitated $\text{Fe}_3\text{O}_4$ , diameter = 200-500 nm, strong tendency to aggregate to particles in the $\mu$ -range	7

EP 1 154 443 A1

Table 1 (continued)

Company	Abbreviation	Description	Code (see Example 1.4)
BASF, Ludwigshafen, Germany	BASF-CE	Beads in the $\mu$ -scale made from metallic iron - BASF Carbonyl iron powder HQ: 10% < 1.04 $\mu\text{m}$ , 50% < 1.91 $\mu\text{m}$ , 90% < 3.71 $\mu\text{m}$ - BASF Carbonyl iron powder SU: 10% < 0,43 $\mu\text{m}$ , 50% < 0.93 $\mu\text{m}$ , 90% < 1.81 $\mu\text{m}$	8 9



Table 2

Code	MI TEOS	Water (ml/100 ml TEOS)	Alcohol (ml/100 ml TEOS)	Alcohol (ml/100 ml TEOS)	Ageing (h)		spray pressur e (bar)	Nozz le	inlet temper ature (°C)	Temperatur e in air before FA (°C)	temperatur e in N <sub>2</sub> after FA (°C)	temperatur e in O <sub>2</sub> after FA (°C)	temperatur e treatment in bottle under air (°C)
0005	1750	13.33	EtOH	50	1		1.5	A	230	250	675	300	300
0009	1750	13.33	EtOH	50	1		1.5	A	230	250	675	300	300
Code	MI TEOS	Water (ml/100 ml TEOS)	Alcohol (ml/100 ml TEOS)	Alcohol (ml/100 ml TEOS)	Ageing (h)	Pigmen t (g/100g Oxid)	Spray pressur e (bar)	Nozz le	inlet temper ature (°C)	Temperatur e treatment in air (°C)	temperatur e in N <sub>2</sub> (°C)	temperatur e- (post)treat ment in air (°C)	temperatur e treatment in bottle under air (°C)
0045	1400	13.33	EtOH	50	0		1.5	A	230	200	675	300	200
0046	250	13.33	EtOH	50	0		5	Büch i	150	200	675	300	200
0047	1300	14.13	EtOH	137	0		1.5	A	230	250	750	200	200
0096	150	14.1	EtOH	141	0	230	6	Büch i	150	200	750	200	200
0097	150	14.1	EtOH	141	0	191	6	Büch i	150	200	750	200	200
0098	210	14.1	EtOH	141	0	230	6	Büch i	150	200	690	200	200
0099	210	14.1	EtOH	141	0	230	6	Büch i	150	200	710	200	200
0100	840	14.1	EtOH	141	0	230	1.5	A	230	200	750	200	200
0101	840	14.1	EtOH	141	0	191	1.5	A	230	200	750	200	200
0102	1300	14.1	EtOH	141	0	230	1.5	A	230	200	750	200	200
0106	840	14.1	EtOH	141	0	230	2.5	A	230	200	750	200	200
0107							3.5	A	230	200	750	200	200
0108							4.3	A	230	200	750	200	200
0109	8000	14.1	EtOH	141	0	230	1.5	A	210	200	750	200	200
0111	1300	14.1	EtOH	141	0	230	1.5	A	210	200	750	200	200
0119	1200	14.6	EtOH	130	0	230	1.5	A	210	200	750	200	200
0124							6	Büch i	150	200	750	200	200
0128	7830	14.1	EtOH	141	0	230	1.5	A	230	200	750	200	200
0129							1.5	A	200	200	750	200	200
0130							4.3	A	200	200	750	200	200
0131							6	A	200	200	750	200	200

EP 1 154 443 A1

Table 3

Sample	Outlet temperature (°C)	Density (g/cm <sup>3</sup> )	Extinction (280 nm)	Extinction (400 nm)	Iron solubility (mg/l)	Magnetic force (g / 250 mg)
RN0005.2E-01	116	3.420	0.037	0.027	< determination limit	16.04
RN0009.1E-01	119	3.155	0.106	0.093	< determination limit	9.50
EI0028.2R-01	118	3.602	0.019	0.024	< determination limit	12.25
RN0045.4R-01	130	3.647	0.032	0.034	< determination limit	9.23
RN0046.7R-01	98	3.866	0.013	0.013	< determination limit	13.12
RN0045.5R-01	120	3.802	0.019	0.017	0.047	9.52
EJ0047.2R-01	118	3.659	0.022	0.018	< determination limit	12.00
EJ0096.5R-01	96	4.203	0.001	0.000	< determination limit	13.53
EJ0096.7R-01	96	4.328	0.000	0.001	< determination limit	18.36
EJ0097.4R-01	96	3.859	0.001	0.000	< determination limit	15.17
EJ0098.8R-01	95	5.588	0.065	0.055	< determination limit	15.76
EJ0099.9R-01	95	5.538	0.103	0.101	0.016	14.13
EJ0100.7R-01	122	4.196	0.027	0.003	< determination limit	16.29
EJ0100.5R-01	126	4.069	0.012	0.012	< determination limit	12.42
EJ0101.4R-01	119	4.079	0.083	0.084	0.015	11.67
EJ0102.2R-01	128	3.668	0.009	0.009	< determination limit	13.36

EP 1 154 443 A1

Table 3 (continued)

Sample	Outlet temperature (°C)	Density (g/cm <sup>3</sup> )	Extinction (280 nm)	Extinction (400 nm)	Iron solubility (mg/l)	Magnetic force (g / 250 mg)
EJ0047.2R-07	118	3.612	0.024	0.022	0.159	11.26
EJ0100.5R-02	127	4.107	0.029	0.023	0.054	14.51
EJ0100.5R-03	127	4.173	0.063	0.045	0.126	10.44
EJ0106.5R-01	127	4.191	0.004	0.004	0.025	10.09
EJ0107.5R-01	127	4.235	0.016	0.009	0.037	10.25
EJ0108.5R-01	127	4.233	0.026	0.026	0.039	11.56
EJ0109.2R-01	110	3.700	0.046	0.043	0.028	11.23
EJ0111.5R-01	117	3.612	0.071	0.036	0.166	16.48
EJ0111.5R-02	121	4.082	0.065	0.040	0.161	15.95
EJ0124.5R-01		3.992	0.001	0.001	0.051	17.57
EJ0128.5R-01	125	4.078	0.023	0.028		8.97
EJ0129.5R-01	92	4.013	0.044	0.043		9.64
EJ0130.5R-01	87	4.022	0.031	0.036		11.70
EJ0131.5R-01	89	3.908	0.033	0.037		11.73
EP0119.5R-01	127	4.110	0.003	0.003	0.079	17.15

Table 4

Lot	BET surface [m <sup>2</sup> /g]	Remarks
EJ0096.5R-01	26.85	Cerac, small spray dryer, 6 bar
EJ0100.5R-01	8.95	Cerac, big spray dryer, 1,5 bar
EJ0101.4R-01	8.47	BASF FA, big spray dryer, 1,5 bar
RN0005.2E-01	3.54	MERCK MMB, big spray dryer, 1,5 bar
RN0009.1E-01	3.25	MERCK BM, big spray dryer, 1,5 bar
EJ0099.9R	0.74	BASF CE-SU, big spray dryer, 6 bar
EJ0100.7R	8.53	STREM, big spray dryer, 1,5 bar

# EP 1 154 443 A1

Table 5

MGP-type	Size of the isolated cores	Constitution	Form	t <sub>1/2</sub> sedimentation [min]	t <sub>1/2</sub> separation [sec]
MMB	3-15 µm	Aggregated	Plates	3.9	14
CERAC	23 nm	Singular	Beads	>> 10	16
STREM	300-500 nm	Aggregated	Beads	4.8	10
BASF-FA	200-300 nm	Aggregated	Needles	4.6	12

Table 6

MGP-sample	t <sub>0,9</sub> (90%-Wert) sedimentation [min]	t <sub>1/2</sub> (50%-Wert) sedimentation [min]
EJ0100.5R-01	0.35	2.78
EJ0108.5R-01	0.62	7.58
EJ0096.5R-01	1.39	19.85

Table 7

MGP	USB [counts] - 0-matrix		SB [counts] - 0.5xGG	
	HIV	HBV	HIV	HBV
EJ0100.5R-01	4997	2277	20380	80292
EJ0100.5R-02	6100	3590	22036	53417
EJ0100.5R-03	4856	2270	19791	65109
EJ0106.5R-01	4427	2263	19030	75128
EJ0107.5R-01	3940	2261	19255	68285
EJ0108.5R-01	3429	2217	20048	80426

Table 8

Sample	MGP lot#	HBV		HCV	
		Ct	S-N	ct	S-N
MP2	EJ0047.2	40.49	19.88	41.68	12.6
MP2	EJ100.5	40.96	21.80	43.08	12.74
MP2	EJ0102.2	41.93	21.39	44.74	10.10
MP2	EJ0108.5	40.09	22.01	47.36	10.61
Pl. ½	EJ0047.2	41.03	18.14	-	-
Pl. ½	EJ100.5	40.12	19.31	-	-
Pl. ½	EJ0102.2	41.81	22.80	44.69	14.30
Pl. ½	EJ0108.5	39.93	21.77	43.27	12.58
Pl. 4/5	EJ0047.2	46.33	12.83	39.54	18.30
Pl. 4/5	EJ100.5	40.82	15.12	38.24	21.48
Pl. 4/5	EJ0102.2	42.49	19.65	39.24	19.05
Pl. 4/5	EJ0108.5	47.33	9.51	39.47	17.81
Pl. 6/8	EJ0047.2	41.08	20.83	49.44	9.46
Pl. 6/8	EJ100.5	40.68	23.16	48.98	10.31
Pl. 6/8	EJ0102.2	40.50	22.49	54.50	6.50
Pl. 6/8	EJ0108.5	38.79	18.60	50.41	8.61
Pl. 6/8	EJ0047.2	44.16	17.26	41.40	10.59
Pl. 6/8	EJ100.5	42.97	18.59	41.01	11.33
Pl. 6/8	EJ0102.2	44.49	12.41	42.18	11.32
Pl. 6/8	EJ0108.5	41.24	18.73	41.46	10.80
Counting statistics: Which type scores better ?					
<i>"standard samples"</i>		<i>"development variants"</i>		<i>total: best type per sample * assay</i>	
MMB : CERAC		MMB : CERAC		MMB : CERAC	
Ct	S-N	Ct	S-N	Ct	S-N
2 : 7	0 : 9	3 : 7	5 : 5	1 : 9	3 : 7
(1 comparison could not be evaluated)					

Table 9

MGP	Description
EJ0096.5R	6.0 bar spraying pressure, 150 °C inlet temperature, Büchi-laboratory equipment. This preparation approximates the characteristics according to the invention very well, see Figure 15.
EJ0111.5R	1.5 bar spraying pressure, 230°C inlet temperature, Nubilos- laboratory equipment
EP0119.5R	1.5 bar spraying pressure, 230°C inlet temperature, Nubilos- laboratory equipment, changed glass composition without Zn-acetate, K-methanolate substituted by K-acetate, with identical stoichiometry
EJ108.5R	4.3 bar spraying pressure, 230°C inlet temperature, Nubilos- laboratory equipment

Table 10

<u>ct-values (HBV)</u>					
<i>ct-calculation via maximum of first differentiation</i>					
Parameter	Titer [sgu/ml]	MGP lot EJ0111.5R-02 AVG	MGP lot EP0119.5R AVG	MGP lot EJ0096.5R AVG	MGP lot EJ0108.5R AVG
HBV	NK	-	-	-	-
	100	46.1	44.1(6/6)	43.4	44.2
	40	47.6	46.5(7/8)	45.5(7/8)	46.7(6/7)
	20	50.6(6/8)	46.1(6/8)	46.8(7/8)	50.0(4/8)
	10	47.6(5/8)	50.1(5/8)	46.8(4/8)	47.7(3/7)
	5	51.2(3/8)	48.6(4/8)	47.8(5/8)	49.7(4/7)
	hit rate	75%	74%	77.5%	67.5%
<i>ct-calculation via cut-off formula</i>					
Parameter	Titer [sgu/ml]	MGP lot EJ0111.5R-02 AVG	MGP lot EP0119.5R AVG	MGP lot EJ0096.5R AVG	MGP lot EJ0108.5R AVG
HBV	NK	-	-	-	-
	100	44.2	41.7(6/6)	41.5	41.9
	40	45.5	44.1(7/8)	42.7(6/8)	45.0(6/7)
	20	47.7(6/8)	43.5(6/8)	44.3(7/8)	47.2(6/8)
	10	45.5(5/8)	47.7(5/8)	44.4(6/8)	45.6(3/8)
	5	49.3(3/8)	45.7(4/8)	45.4(4/8)	46.6(4/7)
	hit rate	75%	74%	77.5%	71%
<u>ct-values (HCV)</u>					
<i>ct-calculation via maximum of first differentiation</i>					
Parameter	Titer [IU/ml]	MGP lot EJ0111.5R-02 AVG	MGP lot EP0119.5R AVG	MGP lot EJ0096.5R AVG	MGP lot EJ0108.5R AVG
HCV	NK	-	-	-	-
	400	42.7	42.5(7/8)	41.8	42.6(7/7)
	80	44.4(7/8)	44.1(6/6)	44.2(7/8)	44.2(7/7)
	60	45.1	44.7(7/7)	44.4(6/7)	45.1(6/6)
	40	46.2(7/8)	45.8(7/7)	43.9(5/7)	44.5(7/7)
	20	46.5(5/8)	46.3(7/7)	45.0(6/8)	47.4(4/8)
	hit rate	90%	97%	84%	88.5%

# EP 1 154 443 A1

ct-calculation via cut-off formula

Parameter	Titer [IU/ml]	MGP lot EJ0111.5R-02 AVG	MGP lot EP0119.5R AVG	MGP lot EJ0096.5R AVG	MGP lot EJ0108.5R AVG
HCV	NK	-	-	-	-
	400	41.8	41.6(7/8)	40.9	41.7(7/7)
	80	44.6(7/7)	44.0(6/6)	43.4(7/8)	44.5(7/7)
	60	44.7	45.3(7/7)	45.1(6/7)	44.3(5/6)
	40	47.9(7/8)	46.1(7/7)	44.7(4/7)	47.5(7/7)
	20	49.6(5/8)	47.2(7/7)	45.3(5/8)	47.4(4/8)
	hit rate	90%	97%	79%	86%

ct-values (HIV)

ct-calculation via maximum of first differentiation

Parameter	Titer [sgu/ml]	MGP lot EJ0111.5R AVG	MGP lot EP0119.5R AVG	MGP lot EJ0096.5R AVG	MGP lot EJ0108.5R AVG
HIV	NK	-	-	-	-
	30	43.2(6/8)	46.9(3/8)	43.9(3/7)	41.9(1/7)
	60	42.7(4/7)	42.6(4/7)	42.8(7/7)	42.4(2/7)
	150	42.4(5/7)	42.0	41.7(6/6)	42.6(6/8)
	300	41.9(5/5)	41.0(5/5)	41.5(6/6)	41.3(6/6)
	600	41.6(7/7)	40.8(6/6)	40.8(5/5)	41.5
	hit rate	79%	76%	87%	64.0%

ct-calculation via cut-off formula





Parameter	Titer [IU/ml]	MGP lot EJ0111.5R AVG	MGP lot EP0119.5R AVG	MGP lot EJ0096.5R AVG	MGP lot EJ0108.5R AVG
HIV	NK	-	-	-	-
	30	44.3(1/8)	47.3(2/8)	46.8(1/7)	-(0/7)
	60	50.3(3/7)	54.1(1/7)	51.4(4/7)	-(0/7)
	150	47.4(5/7)	43.7(5/8)	45.5(5/7)	52.2(2/8)
	300	42.2(5/5)	44.8(5/5)	41.6(4/6)	46.5(6/6)
	600	41.2(7/7)	41.3(5/6)	41.1(5/5)	42.5
	hit rate	62%	53%	59%	44%



Table 11

MGP type	HIV 1		HCV	→	HBV		Performance index	ratio of performance indices
	60 sgu / neg	600 sgu / neg	480 sgu / neg	4800 sgu / neg	40 sgu / neg	400 sgu / neg	Cumulated / weighted / normalized	Without / with shaking
EJ0047.2R (reference)	100	100	100	100	100	100	900	-
EJ0096.5R	55	34	44	74	146	112	709	-
EJ0096.7R	47	47	18	8	116	107	523	-
EJ0097.4R	32	54	29	47	169	132	692	-
RN0045.5R	85	64	76	63	7	84	545	-
RN0046.7R	109	80	43	40	121	135	803	-
RN0045.4R	48	93	112	128	136	96	908	-
EJ0047.2R (reference)	24	24	52	49	93	122	534	0.59
EJ0096.5R	28	23	47	88	102	154	619	0.87
EJ0096.7R	34	23	38	14	99	70	449	0.86
EJ0097.4R	33	36	20	18	101	94	456	0.66
RN0045.5R	53	74	60	25	107	72	610	1.12
RN0046.7R	141	90	16	8	32	40	518	0.64
RN0045.4R	55	113	25	146	78	101	675	0.74

Table 12

particles	HCV-Titer (IVT-RNA)	$\Delta hDNA$	$\Delta ct$	$\Delta S-N$
RN0009.1E = big platelets (3-60 $\mu m$ )	1000 cp/PCR	4000 ng/ml	+2	-6,1
EJ0100.5R = deformed balls (ca. 1-12 $\mu$ -range)			-1	-3,2
EJ0108.5R = deformed balls * (ca. 1-4 $\mu$ -range)			$\pm 0$	-1,2

\* high-pressure variant, see sections 7.2.4.2. & 7.3.1, respectively.

note: (+) $\Delta ct$  = less sensitive (i.e. bias towards false negative results); (-) $\Delta ct$  = more sensitive (bias towards false positive results?)

(-) $\Delta S-N$  = less specific signal generation = negative interference

Table 13

particles (EJ / CERAC throughout)	HCV-Titer (extracted genomic RNA)	$\Delta hDNA$	$\Delta ct$	$\Delta S-N$
EJ0096.5R= design goal *	200 IU/ml sample	4000 ng/ml	-0,95	-8,5
EJ0127.5R = standard			-3,08	-13,89
EJ0129.5R = p-variant			-2,30	-12,62
EJ0130.5R = p-variant			-2,62	-10,57
EJ0131.5R = p-variant			-2,46	-12,41

\* = 0,5-5  $\mu$ -range; > 50% sub- $\mu$ -scale; big surface area (27 m<sup>2</sup>/g BET); perfectly spherical beads

p-variant = spray-dried at elevated pressure (see section 7.3.1).

EP 1 154 443 A1

SEQUENCE LISTING

5 <110> Roche Diagnostics GmbH

<120> Magnetic glass particles, method for their preparation  
and uses thereof

10 <130> 52960AEP engl AB

<140>

<141>

15 <150> EP99122853.7

<151> 1999-11-17

20 <160> 23

<170> PatentIn Ver. 2.1

25 <210> 1

<211> 23

<212> DNA

<213> Artificial Sequence

30 <220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide primer

35 <400> 1

tcagggcaaa actcagctca ccg 23

<210> 2

<211> 23

40 <212> DNA

<213> Artificial Sequence

<220>

45 <223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 2

50 gatgagttcg tgtccgtaca act 23

<210> 3

<211> 30

<212> DNA

55 <213> Artificial Sequence

EP 1 154 443 A1

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 5 oligonucleotide primer (HIV forward)  
  
 <220>  
 <221> modified\_base  
 10 <222> (1)  
 <223> Biotin derivatization  
  
 <400> 3  
 15 agttggagga catcaagcag ccatgcaaat 30  
  
 <210> 4  
 <211> 27  
 20 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 25 <223> Description of Artificial Sequence: Synthetic  
 oligonucleotide primer (HIV reverse)  
  
 <220>  
 30 <221> modified\_base  
 <222> (1)  
 <223> Biotin derivatization  
  
 <400> 4  
 35 tgctatgtca gttcccccttg gttctct 27  
  
 <210> 5  
 <211> 24  
 40 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 45 <223> Description of Artificial Sequence: Synthetic  
 oligonucleotide primer (HCV forward)  
  
 <400> 5  
 50 gcagaaagcg tctagccatg gcgt 24  
  
 <210> 6  
 <211> 24  
 55 <212> DNA  
 <213> Artificial Sequence

# EP 1 154 443 A1

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 5 oligonucleotide primer (HCV reverse)  
  
 <220>  
 <221> modified\_base  
 <222> (1)  
 10 <223> Biotin derivatization  
  
 <400> 6  
 15 ctcgcaagca ccctatcagg cagt 24  
  
 <210> 7  
 <211> 18  
 <212> DNA  
 20 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 25 oligonucleotide primer (HBV forward)  
  
 <400> 7  
 ggagtgtgga ttcgcact 18  
  
 <210> 8  
 <211> 18  
 <212> DNA  
 30 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 35 oligonucleotide primer (HBV reverse)  
  
 <220>  
 <221> modified\_base  
 <222> (1)  
 40 <223> Biotin derivatization  
  
 <400> 8  
 45 tgagatcttc tgcgacgc 18  
  
 <210> 9  
 <211> 20  
 <212> DNA  
 50 <213> Artificial Sequence  
  
 <220>  
 55

EP 1 154 443 A1

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide probe (HIV)

5 <220>  
<221> modified\_base  
<222> (1)  
10 <223> Ruthenium3+-(tris-bipyridyl)-derivatisation

<400> 9  
atcaatgagg aagctgcaga 20

15 <210> 10  
<211> 21  
<212> DNA  
<213> Artificial Sequence

20 <220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide probe (HCV)

25 <220>  
<221> modified\_base  
<222> (1)  
<223> Ruthenium3+-(tris-bipyridyl)-derivatisation

30 <400> 10  
gtcgtgcagc ctccaggacc c 21

35 <210> 11  
<211> 18  
<212> DNA  
<213> Artificial Sequence

40 <220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide probe (HCV)

45 <220>  
<221> modified\_base  
<222> (1)  
<223> Ruthenium3+-(tris-bipyridyl)-derivatisation

50 <400> 11  
agaccaccaa atgcccct 18

55 <210> 12  
<211> 29

EP 1 154 443 A1

<212> DNA  
<213> Artificial Sequence

5 <220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide primer (HIV)

10 <220>  
<221> modified\_base  
<222> (29)  
<223> derivatization with a p-(t-butyl)benzyl-residue

15 <400> 12  
agtgggggga catcaagcag ccatgcaaa

29

20 <210> 13  
<211> 29  
<212> DNA  
<213> Artificial Sequence

25 <220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide primer (HIV)

30 <220>  
<221> modified\_base  
<222> (29)  
<223> derivatization with a p-(t-butyl)benzyl-residue

35 <400> 13  
agtgggggga caccaggcag caatgcaaa

29

40 <210> 14  
<211> 30  
<212> DNA  
<213> Artificial Sequence

45 <220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide primer (HIV reverse)

50 <220>  
<221> modified\_base  
<222> (30)  
<223> derivatization with a p-(t-butyl)benzyl-residue

55 <400> 14



# EP 1 154 443 A1

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide probe (HIV)

5

<220>

<221> modified\_base

<222> (1)

10

<223> Ruthenium3+-(tris-bipyridyl)-derivatisation

<400> 9

atcaatgagg aagctgcaga

20

15

<210> 10

<211> 21

<212> DNA

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide probe (HCV)

25

<220>

<221> modified\_base

<222> (1)

<223> Ruthenium3+-(tris-bipyridyl)-derivatisation

30

<400> 10

gtcgtgcagc ctccaggacc c

21

35

<210> 11

<211> 18

<212> DNA

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide probe (HCV)

45

<220>

<221> modified\_base

<222> (1)

<223> Ruthenium3+-(tris-bipyridyl)-derivatisation

50

<400> 11

agaccaccaa atgcccct

18

55

<210> 12

<211> 29

EP 1 154 443 A1

<212> DNA

<213> Artificial Sequence

5

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide primer (HIV)

10

<220>

<221> modified\_base

<222> (29)

<223> derivatization with a p-(t-butyl)benzyl-residue

15

<400> 12

agtgggggga catcaagcag ccatgcaaa

29

20

<210> 13

<211> 29

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide primer (HIV)

30

<220>

<221> modified\_base

<222> (29)

<223> derivatization with a p-(t-butyl)benzyl-residue

35

<400> 13

agtgggggga caccaggcag caatgcaaa

29

40

<210> 14

<211> 30

<212> DNA

<213> Artificial Sequence

45

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide primer (HIV reverse)

50

<220>

<221> modified\_base

<222> (30)

<223> derivatization with a p-(t-butyl)benzyl-residue

55

<400> 14

# EP 1 154 443 A1

ggtactagta gttcctgcta tgtcacttcc

30

5 <210> 15  
<211> 26  
<212> DNA  
<213> Artificial Sequence

10 <220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide primer (HCV forward)

15 <220>  
<221> modified\_base  
<222> (26)  
<223> derivatization with a p-(t-butyl)benzyl-residue

20 <400> 15  
gcagaaagcg tctagccatg gcgtta

26

25 <210> 16  
<211> 28  
<212> DNA  
<213> Artificial Sequence

30 <220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide (HCV reverse)

35 <220>  
<221> modified\_base  
<222> (28)  
<223> derivatization with a p-(t-butyl)benzyl-residue

40 <400> 16  
gcaagcacc tatcaggcag taccacaa

28

45 <210> 17  
<211> 28  
<212> DNA  
<213> Artificial Sequence

50 <220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide primer (HBV forward)

55 <220>  
<221> modified\_base

EP 1 154 443 A1

<222> (20)

<223> i

5

<220>

<221> modified\_base

<222> (28)

<223> derivatization with a p-(t-butyl)benzyl-residue

10

<400> 17

agaagtcaga aggcaaaaaa gagagtaa

28

15

<210> 18

<211> 27

<212> DNA

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide primer (HBV reverse)

25

<220>

<221> modified\_base

<222> (27)

<223> derivatization with a p-(t-butyl)benzyl-residue

30

<400> 18

cacctctgcc taatcatctc ttgttca

27

35

<210> 19

<211> 32

<212> DNA

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide probe (HIV)

45

<220>

<221> modified\_base

<222> (1)

<223> derivatisation with a  
Pentamethine-di-indocarbocyanine via a  
alkylphosphatidyl-linker (Pharmacia Biotech  
Cy5-N-ethyl-phosphoramidite)

50

55

<220>

<221> misc\_feature

<222> (10)

<223> N represents a

2-(amino-cyclohexyl-)propane-1,3-diol-linker  
derivatised with 6-carboxy-fluorescein (Biogenex  
CX-FAM-phosphoramidite)

<220>

<221> modified\_base

<222> (31)

<223> derivatisation with a 3'-terminal phosphate group

<400> 19

tctgcagctn tcctcattga tggatatcttt ta

32

<210> 20

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide probe (HCV)

<220>

<221> modified\_base

<222> (1)

<223> derivatisation with a

Pentamethine-di-indocarbocyanine via a  
alkylphosphatidyl-linker (Pharmacia Biotech  
Cy5-N-ethyl-phosphoramidite)

<220>

<221> misc\_feature

<222> (15)

<223> N represents a

2-(amino-cyclohexyl-)propane-1,3-diol-linker  
derivatised with 6-carboxy-fluorescein (Biogenex  
CX-FAM-phosphoramidite)

<220>

<221> modified\_base

<222> (31)

<223> derivatisation with a 3'-terminal phosphate group

<400> 20

cgggtgtactc accgnttccg cagaccacta tg

32

5 <210> 21  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence  
  
 10 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 oligonucleotide  
  
 15 <220>  
 <221> modified\_base  
 <222> (1)  
 <223> derivatisation with a  
 Pentamethine-di-indocarbocyanine via a  
 20 alkylphosphatidyl-linker (Pharmacia Biotech  
 Cy5-N-ethyl-phosphoramidite)  
  
 25 <220>  
 <221> misc\_feature  
 <222> (17)  
 <223> N represents a  
 2-(amino-cyclohexyl-)propane-1,3-diol-linker  
 derivatised with 6-carboxy-fluorescein (Biogenex  
 30 CX-FAM-phosphoramidite)  
  
 35 <220>  
 <221> modified\_base  
 <222> (32)  
 <223> derivatisation with a 3'-terminal phosphate group  
  
 40 <400> 21  
 ccaagctgtg ccttggntgg ctttggggca tgg 33  
  
 45 <210> 22  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence  
  
 50 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 oligonucleotide  
  
 55 <220>  
 <221> modified\_base  
 <222> (1)  
 <223> derivatisation with a

Pentamethine-di-indocarbocyanine via a  
alkylphosphatidyl-linker (Pharmacia Biotech  
Cy5-N-ethyl-phosphoramidite)

<220>

<221> misc\_feature

<222> (14)

<223> N represents a

2-(amino-cyclohexyl-)propane-1,3-diol-linker  
derivatised with hexachloro-6-carboxy-fluorescein  
(Biogenex CX-HEX-phosphoramidite)

<220>

<221> modified\_base

<222> (30)

<223> derivatisation with a 3'-terminal phosphate group

<400> 22

tggactcagt cctntggtca tctcaccttc t

31

<210> 23

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide (Aptamer)

<220>

<221> modified\_base

<222> (46)

<223> derivatisation with a 3'-terminal phosphate group

<400> 23

cgatcatctc agaacattct tagcgttttg ttcttgtgta tgatcg

46

## Claims

1. Composition of magnetic glass particles  
**characterized in that**  
the magnetic glass particles contain at least one magnetic object with a mean diameter between 5 to 500 nm.
2. Composition according to claim 1  
**characterized in that**  
the magnetic object has a mean diameter between 10 to 200 nm, preferably between 15 to 50 nm.

3. Composition according to any of the claims 1 to 2  
**characterized in that**  
the half-life period for the sedimentation of a 3 mg/ ml weight-per-volume suspension of the composition in iso-  
propanol is more than 3 min.
4. Composition according to claim 3  
**characterized in that** the half-life period is more than 6 min.
5. Composition according to any of the claims 1 to 4  
**characterized in that** the magnetic object has a mean diameter of 23 nm.
6. Composition according to claim 1 or 5  
**characterized in that** the diameter ratio of the magnetic body to the glass shell is less than 1 to 10.
7. Composition according to any of the claims 1 to 6  
**characterized in that** the magnetic glass particles have a mean diameter between 0,5  $\mu\text{m}$  and 5  $\mu\text{m}$ .
8. Composition according to any of the claims 1 to 7  
**characterized in that**  
the magnetic glass particles have a mean diameter between 1  $\mu\text{m}$  to 2  $\mu\text{m}$ .
9. Composition according to any of the claims 1 to 8  
**characterized in that** the magnetic glass particles are microporous.
10. Composition according to any of the claims 1 to 9  
**characterized in that**  
the pore surface of the magnetic glass particles is less than 10 % of the total surface.
11. Composition according to any of the claims 1 to 10  
**characterized in that** the magnetic object is superparamagnetic.
12. Composition according to any of the claims 1 to 10  
**characterized in that** the magnetic object is ferrimagnetic or ferromagnetic.
13. Composition according to any of the claims 1 to 12  
**characterized in that** the magnetic object comprises iron or iron oxide.
14. Composition according to claim 13  
**characterized in that** the iron oxide is  $\text{Fe}_3\text{O}_4$  or  $\gamma\text{-Fe}_2\text{O}_3$ .
15. Composition according to any of the claims 1 to 14  
**characterized in that** the magnetic glass particles have a surface area of more than 4  $\text{m}^2/\text{g}$ .
16. Composition according to claim 15  
**characterized in that**  
the magnetic glass particles have a surface area between 5 to 100  $\text{m}^2/\text{g}$ , preferably in the range of 10 to 50  $\text{m}^2/\text{g}$ , most preferably in the range of 15 to 30  $\text{m}^2/\text{g}$ .
17. Composition according to any of the claims 1 to 16  
**characterized in that**  
the magnetic glass particles are substantially spherical.
18. Suspension containing a composition of magnetic glass particles in a liquid according to any of the claims 1 to 17.
19. Suspension according to claim 18  
**characterized in that**  
the liquid comprises an alcohol.



20. Suspension according to claim 19  
**characterized in that**  
the alcohol is isopropanol or ethanol.
- 5 21. Suspension according to claim 19  
**characterized in that**  
the liquid is 70 % (V/V) ethanol.
22. Suspension according to claim 18 **characterized in that** the liquid is a buffered aqueous solution.
- 10 23. Suspension according to claim 22 **characterized in that** the solution is buffered by Tris-hydroxymethylamine, phosphate, N- (2-Hydroxyethyl)piperazine-N'- (2-ethanesulfonic acid) or salts thereof.
- 15 24. Suspension according to any of the claims 22 to 23  
**characterized in that**  
the solution further contains substances modifying the ionic strength or metalcomplexing agents.
- 20 25. Suspension according to any of the claims 22 to 24  
**characterized in that** the suspension additionally contains DNA or RNA.
- 25 26. Suspension according to any of the claims 22 to 24  
**characterized in that**  
the suspension contains additionally DNA or RNA or both in a mixture with one or more compounds selected from the group of proteins, fatty acids, carbohydrates or any other biological material.
27. Suspension according to any of the claims 18 to 26  
**characterized in that** the suspension additionally contains a chaotropic agent.
- 30 28. Suspension according to claim 27  
**characterized in that**  
the chaotropic agent is selected from the group consisting of sodium iodite, sodium perchlorate, guanidinium thiocyanate, guanidinium isothiocyanate or guanidinium hydrochloride.
- 35 29. Suspension according to any of the claims 28 to 29  
**characterized in that**  
the chaotropic agent is present in a concentration between 2 and 8 mol/l, and preferably between 4 and 6 mol/l.
- 40 30. Suspension according to any of the claims 18 to 29  
**characterized in that**  
the suspension contains 5 to 60 mg/ ml of a composition according to any one of the claims 1 to 17.
31. A tube containing a composition according to any of the claims 1 to 17 or a suspension according to any of the claims 18 to 30.
- 45 32. A storage container containing a composition according to any of the claims 1 to 17 or a suspension according to any of the claims 18 to 30.
33. A kit of parts containing a tube according to claim 31 or a storage container according to claim 32.
- 50 34. A kit of parts according to claim 33 further containing washing solution or eluent.
35. A kit of parts according to any of the claims 33 to 34 further comprising reagents suitable for the purification of a nucleic acid.
- 55 36. Use of a composition according to any of the claims 1 to 17 for the preparation of an suspension.
37. Use of a suspension according to any of the claims 18 to 30 for the purification of nucleic acids.

38. Use of a kit of parts according to any of the claims 33 to 35 for the purification of nucleic acids.

39. Method for the production of a composition of magnetic glass particles according to any of the claims 1 to 17 comprising the steps of

- a) suspending magnetic objects with a diameter between 5 and 500 nm in a sol,
- b) spray-drying the suspension in a two-nozzle spray-drier, and
- c) sintering the spray-dried powder.

40. Method according to claim 39

**characterized in that**

the inlet temperature of the two-nozzle spray-drier is between 120 °C and 500 °C, the outlet temperature is chosen according to the boiling point of the sol and the spray pressure is at least 3 bar.

41. Method according to any one of the claims 39 to 40

**characterized in that**

the inlet temperature of the two-nozzle spray-drier is between 170 °C and 230 °C, preferably between 190 °C and 210 °C.

42. Method according to any one of the claims 39 to 41

**characterized in that**

the inlet temperature of the two-nozzle spray-drier is 200 °C.

43. Method according to any one of the claims 39 to 42

**characterized in that**

the spray pressure is between 4 and 6 bar.

44. Method according to any one of the claims 39 to 43

**characterized in that**

the sol contains ethanol as solvent.

45. Method according to claim 44

**characterized in that**

the outlet temperature is between 50°C and 300°C.

46. Method according to any one of the claims 44 to 45

**characterized in that**

the outlet temperature is between 90°C and 100°C.

47. Method according to any one of the claims 39 to 46

**characterized in that**

the sinter temperature is between 400°C to 1200°C, preferably between 720°C and 770°C.

48. Magnetic glass particles obtainable by a process as claimed in any of the claims 39 to 47.

49. Procedure for isolating a biological material comprising

- a) bringing a sample that contains the biological material in a liquid in contact with a composition according to any one of the claims 1 to 17, magnetic glass particles according to claim 48 or a suspension according to any of the claims 18 to 30 under conditions in which the biological material binds directly to the glass surface, and
- b) separating the biological material from the liquid.

50. Procedure according to claim 49, **characterized in that** the biological material is a nucleic acid.

51. Procedure according to claim 49, **characterized in that** the biological material contains a mixture of nucleic acids, wherein the target nucleic acid or target nucleic acids is/ are present in low abundance.

52. Procedure according to any one of the claims 49 to 51,  
**characterized in that**  
the separation is accomplished with the aid of a magnet.
- 5 53. Procedure according to any of the claims 49 to 52,  
**characterized in that**  
the magnetic particles are not premagnetized when brought into contact with the sample.
- 10 54. Procedure according to any of the claims 49 to 53  
**characterized in that**  
the procedure is automatized.
- 15 55. Procedure according to any of the claims 49 to 54  
**characterized in that**  
the procedure is in a high-throughput format.
- 20 56. Procedure according to any of the claims 49 to 55  
**characterized in that**  
during the procedure a suspension according to any of the claims 18 to 26 is taken from a storage container and  
partial volumes of the suspension are added to different reaction vessels.
- 25 57. Procedure according to any of the claims 49 to 56  
**characterized in that**  
the nucleic acid is detected after the purification.
58. Procedure according to any of the claims 49 to 57  
**characterized in that**  
the nucleic acid is detected after an amplification step.
- 30 59. Procedure according to any of the claims 57 to 58  
**characterized in that**  
the nucleic acid is detected by a process comprising:
- 35 a) contacting the sample with an oligonucleotide containing a sequence complementary to a region of the  
target nucleic acid and a labeled oligonucleotide containing a sequence complementary to a second region  
of the same target nucleic acid sequence strand, but not including the nucleic acid sequence defined by the  
first oligonucleotide, to create a mixture of duplexes during hybridization conditions, wherein the duplexes  
comprise the target nucleic acid annealed to the first oligonucleotide and to the labeled oligonucleotide such  
that the 3'-end of the first oligonucleotide is adjacent to the 5'-end of the labeled oligonucleotide;
- 40 b) maintaining the mixture of step a) with a template-dependent nucleic acid polymerase having a 5' to 3'  
nuclease activity under conditions sufficient to permit the 5' to 3' nuclease activity of the polymerase to cleave  
the annealed, labeled oligonucleotide and release labeled fragments; and  
c) detecting and/ or measuring the signal generated by the hydrolysis of the labeled oligonucleotide.
- 45 60. Procedure according to any of the claims 58 to 59  
**characterized in that**  
the detection is carried out in the presence of a blocking oligonucleotide.
- 50 61. Procedure according to claim 60  
**characterized in that**  
the blocking oligonucleotide is an aptamer.
62. Procedure according to claim 61  
**characterized in that**  
the aptamer has the sequence SEQ ID NO: 23.
- 55 63. Procedure according to any of the claims 60 to 62, **characterized in that** the amplification and detection reaction  
is carried out in a homogeneous solution-phase multiplex assay format for the simultaneous detection of multiple

targets.

64. Procedure according to any of the claims 61 to 63, **characterized in that** for at least 5 cycles of the polymerase chain reaction, the annealing temperature is less than 8°C, preferably less than 3°C above the dissociation temperature of the polymerase-aptamer complex.

Figure 1

Flow scheme for the production by sol synthesis & spray drying:




Figure 2

Flow scheme for the preparation processing of the premature particles

Precondensation by temperature treatment (4h/200°C) in air for the stabilisation of the surface



Final condensation and sintering under inert atmosphere (N<sub>2</sub>) through treatment at high temperatures (1h, 750°C) => pigment cores surrounded by a weakly subcooled melt



Rapid cooling => magnetic pigment core-glass coated-particle = MGP



Temperature treatment in the air (4h, 200°C) = Oxidation of the glass shell



Preparation of the non-aggregating fraction by the use of a sieve



Bottling of the MGP powder, then 4h/200°C temperature treatment



Cooling to approximately 80°C, Closing of the bottle with foil and screw top



Storage of the MGP powder ==> Suspension in R-OH (e.g. isopropanol)

Figure 3




Figure 4





Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11





Figure 12



Roche Diagnostics GmbH 5296/0A/EP AB



Figure 13




Figure 14a





Figure 14b







Figure 15

Roche Diagnostics GmbH 52960/0/EP AB

Figure 16



Roche Diagnostics GmbH 52960A/EP AB



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 00 11 0165

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	CHAKRAVORTY D ET AL: "Nanocrystalline nickel-zinc ferrite prepared by the glass-ceramic route" JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, NL, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 164, no. 1, 1 November 1996 (1996-11-01), pages 256-260, XP004055624 ISSN: 0304-8853 * page 259, column 1 *	1,2,5, 12,13	H01F1/00 H01F1/44 C12N15/10 C12Q1/68 B03C1/01
X	PAL M ET AL: "Preparation of nanocrystalline barium hexaferrite in a glass medium" NANOSTRUCTURED MATERIALS, US, PERGAMON PRESS, TARRYWOOD, NY, vol. 8, no. 6, 1 September 1997 (1997-09-01), pages 731-738, XP004097109 ISSN: 0965-9773 * page 738, paragraph 2 *	1,2,12, 13	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
D,X	EP 0 757 106 A (TOYO BOSEKI) 5 February 1997 (1997-02-05)  * page 2, line 1 - line 7 * * page 4, line 38 - line 52; claims 1-3,6 *	1-4,6,7, 12-14, 18,35, 37,38, 49,50,52	H01F C12N C12Q B03C
D,A	DE 195 20 964 A (INST NEUE MAT GEMEIN GMBH) 12 December 1996 (1996-12-12) * claims 1-3,7,8,11; examples 3-5 *	1,2, 11-14,39	
D,A	WO 95 06652 A (PROMEGA CORP) 9 March 1995 (1995-03-09)		
The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>11 September 2000</b>	Examiner <b>Decanniere, L</b>
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/92 (P4/C21)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 11 0165

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

11-09-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0757106 A	05-02-1997	JP 2965131 B	18-10-1999
		JP 9019292 A	21-01-1997
		US 5945525 A	31-08-1999
DE 19520964 A	12-12-1996	AT 179200 T	15-05-1999
		AU 5818296 A	09-01-1997
		CZ 9700404 A	16-07-1997
		DE 59601722 D	27-05-1999
		WO 9641840 A	27-12-1996
		EP 0830429 A	25-03-1998
		EP 0777633 A	11-06-1997
		ES 2130829 T	01-07-1999
		WO 9641773 A	27-12-1996
		JP 11507412 T	29-06-1999
		JP 10504013 T	14-04-1998
		PL 318504 A	23-06-1997
WO 9506652 A	09-03-1995	AU 689815 B	09-04-1998
		AU 8010094 A	22-03-1995
		CA 2170604 A	09-03-1995
		EP 0723549 A	31-07-1996
		JP 9505724 T	10-06-1997
		US 5658548 A	19-08-1997
		US 5808041 A	15-09-1998

ERO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82